AUTHOR INDEX

VOLUME 17

Abrams, William B., 847
Acred, P., 876
Adelman, Martin, 649
Aird, M. Y., 554
Albritton, William L., 897
Alexander, G. A., 901, 937
Alexander, Gary A., 516, 740
Allen, James C., 37
Allen, John G., 973
Altschaefl, JoEllen, 798
Amatnieks, Yuri E., 379
Anderson, Donald C., 470
Anderson, J. D., 554
Anderson, R., 322
Andrews, J. M., 84, 298, 884
Arancibia, A., 199
Arbeit, Robert D., 947
Archer, Gordon L., 269, 280
Aron, Gary M., 1032
Artis, William M., 725
Arvesen, James N., 813
Asahi, Yoshinari, 912
Auperin, David, 1034
Avent, C. Kirk, 286
Aviv, Haim, 510
Ayisi, Nanna K., 558
Aziz, K. M. S., 477
Aznar, Javier, 129

Babiuk, Lorne A., 558
Bailey, P. J., 549
Baker, Carolyn N., 757
Balkwill, D. L., 506
Ballester, J. M., 784
Ballester, M., 784
Banner, William, Jr., 691
Barada, F. A., Jr., 961
Barry, A. L., 464, 743
Barry, Arthur L, 750
Bartlett, John G., 695
Barza, Michael, 707
Bayer, Arnold S., 359
Beam, Thomas R., Jr., 37
Bedford, K. A., 84, 298, 884
Bedows, Elliott, 890
Belaich, J. P., 784
Ben-Ari, Gur, 905
Bergeron, Michel G., 383
Berman, Steven J., 251
Bernstein, Jack M., 770
Bhuwapathanapun, S., 519
Birnbaum, Jerome, 993
Blair, Andrew D., 89
Blanco, Jorge D., 1004
Bock, Bonnie V., 217
Bodey, Gerald P., 92, 423, 834, 1008
Borobio, M. Victoria, 129
Borowski, Edward, 699
Botstein, David, 537
Boughton, William H., 251
Bowden, George H. W., 897
Brau, Carmen J., 286
Brauman, H., 530
Brodey, Mitchell V., 599
Brown, William J., 629
Bryan, L. E., 71
Bulger, Robert R., 393
Bundtzen, Robert W., 599
Burckart, Gilbert, 691
Burkholder, Ernest, 461
Busson, R., 8

Casillas, Edmundo, 55
Castaneda, Yolanda S., 1004
Castric, Peter A., 732
Chaslus-Dancla, Elizabeth, 327
Chern, M. Myra, 654
Cherne, John E., 20
Cherubin, Charles, 675
Choey, Irene, 389
Chow, Anthony W., 359
Chung, Menger, 184
Colwell, R. R., 512
Colwell, Rita R., 477
Conrad, Robert S., 615
Cools, Willy, 922
Cordera, Cynthia S., 258
Cornelissen, Frans, 922
Costello, Robert, 184
Cote, Kim M., 865
Couch, Robert B., 642
Counts, George W., 89
Cousins, G., 549
Craig, William A., 599
Crawford, S. A., 901, 937
Crawford, Sharon A., 516
Crokaert, F., 856
Crossley, Kent B., 654
Crowther, Carol, 71

Dalhoff, A., 738
Darby, Graham, 209
Daschner, F. D., 738
Daugherty, J. Patrick, 443
Davis, A Todd, 461
Davis, William B., 663
De Clercq, E., 8
de Godoy, Cid V. Franco, 526
Delgado, Dennis G., 286
DeLuca, Neal, 63
Descamps, J., 8
De Somer, P., 8
DeVoe, I. W., 715
Doern, Gary V., 24
Douglas, R. Gordon, Jr., 770, 865
Drake, Stephanie, 642
Dubois, J., 1001
Duksin, Dan, 1014
Durack, David T., 43, 488
Dzink, Joanne, 695

Edelstein, Paul H., 217
Edwards, Deborah J., 488
Edwards, John E., Jr., 484
Eley, Adrian, 397
Elliott, Clayton, 247
English, A. R., 623

Fainstein, Victor, 254
Feigin, Ralph D., 470
Feldman, William E., 669
Ferguson, Roger K., 847
Ferrari, Franco A., 87
Field, Hugh J., 209
Fillastre, J. P., 344
Fitter, Mindy S., 120
Fox, J. J., 803
Francisco, Waldemar, 526
Franker, Colin K., 151
Frimodt-Möller, Niels, 599
Frogge, Judith A., 99
Fu, Kwung P., 583
Fuchs, P. C., 743
Fuchs, Peter C., 750
Fukada, Shigemi, 157

Gaines, Stuart A., 428
Galvao, Paulo A. Ayrosa, 526
Garcia, Fernando, 129
Gatmaitan, Bienvenido G., 49
Gavan, T. L., 464, 743, 824
Gavan, Thomas L., 750
Geary, Terence D., 776
Georgopoulos, A., 779
Gerber, Nancy N., 636
Gerberick, G. Franklin, 732
Gerding, Dale N., 20, 273, 1023
Gerlach, E. H., 743
Gerlach, E. Hugh, 750
Gibbs, Ronald S., 1004
Gilleland, H. E., Jr., 615
Gilman, R. H., 402
Girard, A. E., 623
Godin, M., 344
Gonzalez, C., 199
Gonzalez, G., 199
Gooch, W. Manford III, 691
Goodson, J. Max, 193
Gorbach, Sherwood L., 707
Gordon, Jeffrey M., 193
Gordon, Morris A., 120

Grabow, Gisela, 322
Graham, S. O., 980
Granade, Timothy C., 725
Gray, P. P., 519
Greenwood, David, 397
Guay, R., 1001
Guerrant, R. L., 961
Guillot, Jean-François, 327
Gupta, V. Sagar, 558
Gurusiddaiah, S., 980
Guttman, J., 199
Guze, Lucien B., 359
Guzman, Manuel A., 537

Hakenbeck, Regine, 364
Hall, Caroline B., 770
Hall, Wendell H., 20, 273, 1023
Hallick, Lesley M., 24
Hansen, Sharon L., 686
Harding, S. M., 876
Harford, S., 798
Harned, Cindy L., 969
Harper, P. B., 876
Harper, Paul B., 929
Hashimoto, T., 908
Hashizume, Terutaka, 912
Haspel, Jacob, 905
Hattori, Yukio, 337
Haughey, David B., 649
Hawley, Robert J., 372
Hayden, Frederick G., 865
Hedges, R. W., 537
Henderson, David K., 484
Hendlin, David, 679
Herman, R. Peter, 170, 450
Hermans, John M. H., 350
Hess, John R., 251
Hinds, David B., 470
Hinkle, Anne M., 423
Hirai, K., 355
Hirai, Keiji, 103
Hirose, Toshiharu, 157
Hirschman, Shalom Z., 608
Hirsh, Dwight C., 313
Hixon, Sharon C., 443
Höffler, Ulrich, 943
Holbrook, Anne M., 847
Holloway, B. W., 71
Holloway, Bruce W., 293
Holmes, King K., 89
Horikawa, Susumu, 1
Horne, Diane, 235
Hottendorf, Girard H., 188
Hruska, Jerome F., 770
Huff, Thomas, 969
Humbert, G., 344
Humbert, Guy, 675
Huq, Imdadul, 477
Hyams, David M., 263

Iannitelli, Robert C., 861
Ichikawa, Masatsune, 109
Ikawa, Miyoshi, 861
Ikeda, Kazuyoshi, 1030
Inamine, Edward, 679
Ingram, J. M., 715
Inoue, M., 355
Inoue, Matsuhisa, 103, 736
Irikura, Tsutomu, 103
Irvin, James D., 1032
Islam, S., 402
Issell, Brian F., 1008
Ito, Akira, 103
Ito, Norikazu, 157
Iyobe, S., 355
Izawa, Akio, 763

Jaffé-Brachet, Aline, 327
Janicke, David M., 649
Jenkin, Howard M., 699
Jimenez, Rufino, 129
John, Joseph F., 179
Johnson, James E., 740
Johnson, K. G., 789
Johnson, K. R., 554
Johnson, Margaret M., 20
Jones, A. S., 8
Jones, David T., 838
Jones, N. R., 743
Jones, R. N., 464
Jones, Ronald N., 750, 757
Jorgensen, J. H., 901, 937
Jorgensen, James H., 516, 740

Kahan, Frederick M., 993
Kahan, Jean S., 993
Kameda, Yasuo, 302
Kaper, J. B., 512
Kaper, James, 477
Kaplan, Sheldon L., 470
Kataoka, Yuko, 124
Katz, Ehud, 1014
Kawabe, Haruhide, 138
Kaye, Donald, 957
Kaye, Karen, 957
Keith, Alec, 63
Keleti, Eva, 591
Kennell, Wiebke L., 144
Kenny, Margaret A., 55
Kern, Brian A., 679
Kesado, Tadataka, 912
Kidder, George W., 567
King, Anna, 165
Kirby, Susan M., 876
Klein, Ehud, 905
Klimek, Joseph, 595
Knight, Paul R., 890
Knight, Vernon, 642
Kobasa, William, 957
Kobayashi, Fujio, 337
Koga, Hiroshi, 103
Komatsu, Toshiaki, 763
Komatsu, Yoshihide, 316
Kono, Megumi, 16
Korones, Sheldon B., 691
Koshi, Tomoyuki, 337
Koster, F., 402
Kozak, Alan J., 1023
Krogstad, Donald J., 965
Kropp, Helmut, 993
Kuninaka, Akira, 109, 1030
Kurashige, Satonori, 138, 203
Kuwahara, Shōgo, 302

LaFont, Jean-Pierre, 327
Lang, Selwyn D. R., 43, 488
Langmaack, H., 738
Lapa, Edward W., 120
Lauermann, Michael W., 707
Lauwers, William F., 922
Lawson, Ronald D., 834
Leary, Patricia L., 947
LeBlanc, Barbara M., 92, 423
LeBlanc, Donald J., 372
Lechevalier, H. A., 636
Lee, Francis H., 188
Lee, Linda N., 372
Lees, Lorna J., 973
Legaspi, Reuben C., 49
Lerman, Stephen J., 101
Lerner, A. Martin, 49
Leroy, A., 344
Leroy, Annie, 675
Lessard, Celine, 383
Letarte, R., 1001
Levin, Myron J., 947
Levison, Matthew E., 226
Levy, Hilton B., 49
Lindsay, Marjorie, 120
Line, Verle D., 842
Ling, Gerald V., 313
Lismont, M. J., 856
Lockman, H. A., 512
Lockman, Hank A., 477
Lomar, André Villela, 526
Loock, Christine A., 406
Lopez, C., 803
Lynd, Frederick T., 144

Machida, Haruhiko, 109, 1030
MacKenzie, C. R., 789
Maclean, Ian W., 897
Madsen, Paul O., 599
Maigaard, Sven, 599
Malewicz, Barbara, 699
Mandel, Adrian D., 969
Mandell, Gerald L., 658
Marconi, Massimo, 87
Margalith, Eva, 1014
Markowitz, Sheldon M., 80
Mason, Edward O., Jr., 470
Masuda, Gohta, 334
Matsen, John M., 417
Matsubara-Nakano, Michiko, 124
Matsuura, M., 908
Matsuura, Shinzō, 302
Maudgal, P. C., 8
Mayama, Mikao, 302
McCarthy, Laurence R., 954
McCracken, George H., Jr., 406
McDonald, I. J., 789
McDowell, Thomas D., 572

McKie, James, 813
Mclaughlin, J., 402
McNeill, William F., 179
McNicol, L. A., 512
McNicol, Lore Anne, 477
Mead, Karen E., 654
Medeiros, Antone A., 537
Meldrum, J. Blair, 558
Meyer, Philip W., 101
Meyer, Richard D., 217
Meyers, Burt R., 608
Michel, Jacques, 13
Middelbeek, Evert J., 350
Minshew, Barbara H., 55
Mirelman, David, 115
Mirrett, Stanley, 412
Missotten, L., 8
Mitsuhashi, S., 355, 908
Mitsuhashi, Susumu, 103, 138, 203, 736, 763
Mizuno, Yoshihisa, 1030
Moellering, Robert C., Jr., 30
Moffitt, Steven, 669
Montgomerie, John Z., 484
Moody, M. R., 871
Moorman, David R., 658
Morgan, Denis J., 132
Morgan, John R., 544
Morris, M. J., 871
Morrison, Joan, 484
Morrison, Joan O., 359
Morse, Stephen A., 24
Mossie, Kevin G., 838
Murakawa, Takeo, 157
Murray, Barbara E., 30
Murray, Patrick R., 474
Musgrave, James E., 251
Musher, Daniel M., 254
Muytjens, Harry L., 350
Mychajlonka, Myron, 572

Nagate, Takatoshi, 203, 763
Nahrwold, Michael L, 890
Nakamoto, Shoji, 157
Nakamura, Kishio, 334
Nakamura, Nobuo, 138
Nakazawa, H., 908
Namiki, Sinjuro, 763
Neirinck, L. G., 715
Nerland, Donald E., 969
Neu, Harold C., 263, 583
Nicas, Thalia, 71
Niederau, Walter, 943
Nightingale, Charles H., 595
Nilsson, Lennart, 918
Nishi, Takeshi, 494
Nishida, Minoru, 157
Nishikawa, Tohru, 316
Nolan, Linda L., 567
Norden, Carl W., 591
Norrby, Ragnar, 526
Nuchamowitz, Yael, 115

O'Brien, Thomas F., 537
Ocak, Adil, 443
O'Callaghan, Cynthia H., 876, 929
Ogawara, Hiroshi, 1, 124
O'Grady, Francis, 397
O'Hara, Koji, 16
Ohashi, Yoichi, 138
Ohmura, Sadaburni, 763
O'Leary, Thomas D., 776
Oosthuizen, Robyn, 322
Opfer, Bonnie J., 20, 273
Overman, Timothy L., 612

Pagani, Ambrogio, 87
Pan, Theresa, 834
Pancoast, Stephen J., 263
Parquette, Arlene R., 965
Parsons, James N., 226
Pearson, Neil, 397
Pechère, J. C., 1001
Pekarek, Robert S., 258
Perea, Evelio J., 129
Perfect, John R., 43
Peterson, Lance R., 20, 1023
Pfeffer, Morris, 188
Phillips, Ian, 165
Poirier, Robert H., 144
Pollock, Helen M., 55
Pulverer, Gerhard, 943

Quintiliani, Richard, 595

Rahaman, M. M., 402
Ralph, Edward D., 379
Ratcliff, Rodney M., 776
Raymond, Kenneth, 132
Reimer, Larry G., 412
Rein, Michael F., 247
Reinhardt, Albert, 1034
Reller, L. Barth, 412
Remmers, E. F., 512
Remmers, Elaine F., 477
Retsema, J. A., 623
Robb, Frank T., 838
Rogers, J. Douglas, 847
Rogez, Jean-Paul, 675
Rollins, Larry D., 428
Romano, Joseph M., 226
Rosner, Arie, 510
Ross, Donald G., 537
Rotschafer, John C., 654
Royle, Pamela L., 293
Rubinstein, Ethan, 905
Ruby, Annette L., 313
Ryan, D. M., 876

Saino, Yushi, 337
Sakamoto, Hiroshi, 157
Saku, Kazue, 334
Sands, Jeffrey, 1034
Saneyoshi, Mineo, 109
Sansonetti, Philippe, 327
Sato, Kenichi, 736
Sato, Kiyoshi, 138
Schaad, Urs B., 406
Schentag, Jerome J., 649
Schimpff, S. C., 871
Schoenknecht, F. D., 824
Schoenknecht, Fritz D., 55
Schrogie, John J., 847
Schutze, E., 779
Schwarzkopf, Renata, 905
Selwyn, Murray, 428
Seo, John, 813
Shahidi, Azra, 389
Shannon, Kevin, 165
Shaw, S. Akram, 636
Shiomi, Yoko, 16
Shockman, Gerald D., 572
Siccardi, Antonio G., 87
Siebers, Kathy G., 24
Siemsen, Arnold M., 251
Simpson, Iain N., 929
Smith, Kendall O., 144
Smith, Terry L., 834
Smyth, Robert D., 188
Snipes, Wallace, 63
Snow, G. A., 549
Socransky, Sigmund S., 193
Sommers, H. M., 743
Sommers, Herbert M., 750
Sonnenfeld, Gerald, 969
Spira, W. M., 512
Spira, William M., 477
Sprow, Nancy, 669
Srulevitch, Elina, 608
St. Clair, Patricia J., 1004
Stefanoni, Renzo, 87
Steinkraus, Gregory E., 954
Stessman, Jochanan, 13
Stessman, Pnina, 13
Stevens, S. E., Jr., 506
Stringfellow, Dale A., 455, 988
Strougo, Lucia, 608
Stumm, Claudius, 350
Sugihara, Jared G., 251
Sundelof, Jon G., 993
Suzue, Seigo, 103
Swenson, Jana M., 247
Symchowicz, Samson, 184

Tadmor, Amnon, 905
Tally, Francis P., 707
Taneja, Ashok K., 558
Tarpay, Martha, 364
Tenenbaum, Marvin J., 269
Thaniyavarn, Suthep, 969
Theron, Annette, 322
Thoma, G., 738
Thomas, Jonah E., 443
Thomas, Marion L., 406
Thornsberry, C., 824
Thornsberry, Clyde, 247, 757
Tight, Robert R., 229
Tomasz, Alexander, 235, 364, 434
Toothaker, Roger D., 599
Trottier, Sylvie, 383

Tsuchiya, Kanji, 494

Valsamis, J., 530
van Cutsem, Jan M., 922
Van den Bossche, Hugo, 922
Vanderhaeghe, H., 8
Van der Linden, M. P., 856
Van Harken, Donald P., 188
Van Rensburg, A. J., 322
Vastola, A. Paul, 798
Vazquez, Guillermo J., 280
Verbist, Ludo, 807
Verhaegen, Jan, 807
Verhelst, G., 8
Vickers, Richard M., 96
Vlasses, Peter H., 847
Voll, M. J., 512
Voll, Mary J., 477
Vu-Trong, K., 519

Waatti, Priscilla E., 629
Wagner, Kenneth F., 89
Walker, Clay B., 193
Walker, Cynthia Needham, 730
Walker, R. T., 8
Washington, J. A., II, 824
Washington, John A. II, 393
Watanabe, K. A., 803
Weaver, Susanne S., 92
Weber, Morton M., 170, 450
Weed, Sheldon D., 988
Welling, Peter G., 599
West, Susan E. H., 288
White, A. J., 549
White, Arthur C., 229
Wilkins, Tracy D., 288
Willemsens, Gustaaf, 922
Williams, Keith E., 544
Williams, Robert D., 428
Wills, P. J., 84
Wilson, Samuel Z., 642
Wise, R., 84, 298, 884
Wong, Eugene G. C., 251
Woods, David R., 838
Wright, Donald N., 417
Wright, Walter E., 99, 842
Wyde, Philip R., 642

Yajima, Taro, 334
Yogev, Ram, 461
Yoshida, Tadashi, 302
Yoshino, Hiroshi, 109, 1030
Young, Edward J., 254
Young, V. M., 871
Yourassowsky, E., 530, 856
Yu, Victor L., 96

Zaske, Darwin E., 654
Zighelboim, Sonia, 434
Zuravleff, Jeffrey J., 96

SUBJECT INDEX

VOLUME 17

AB206
  E. coli, 203
  gram-negative bacteria, 203, 763
  K. pneumoniae, 203
  P. morganii, 203
  Proteus, 763
  Serratia, 763
3-Acetoxymethyl cephalosporins
  hydrolysis, 99
  lysed whole blood, 99
Acinetobacter
  aminoglycoside-modifying enzymes, 30
Acycloguanosine
  herpes simplex virus, 144
  9-(2-hydroxyethoxymethyl)guanine, 144
Acyclovir
  herpes simplex virus, 209
  human fibroblasts, 947
  mice, 209
  peripheral blood mononuclear cells, 947
Adenylate nucleotide pool
  biosynthesis of tylonolide precursors, 519
  S. fradiae, 519
Adriamycin
  cytotoxicity, 443
  respiratory-deficient mutants, 443
  Saccharomyces uptake, 443
Aerococcus viridans
  viridicin, 784
Aeromonas hydrophila
  antimicrobial susceptibility, 612
  aquatic environments, 477
  drug resistance, 477
Aerosols
  amantadine, 642
  ribavirin, 642
Agar dilution
  compared with broth-disk elution, 740
Agmenellum quadruplicatum
  mesosome-like structures, 506
  penicillin G, 506
Alafosfalin
  alone, 973
  combined with cephalexin, 973
  humans, 973
5-Alkenyl derivatives
  1-β-D-arabinofuranosyluracil, 1030
AM-715
  antibacterial activity, 103
  nalidixic acid analog, 103
Amantadine aerosol
  influenza A and B, 642
  mice, 642
Amikacin
  420 blood culture isolates, 412
  compared with moxalactam (LY127935), 412
  compared with netilmicin, 217
  efficacy and toxicity, 217
  eighth-nerve toxicity, 707
Aminoglycoside
  sporaricin A, 337
  UK31214, 298
Aminoglycoside antibiotic
  KW1070, 138
Aminoglycoside antibiotics
  candidacidal activity, 87
  human neutrophil leukocytes, 87
Aminoglycoside-modifying enzymes
  Acinetobacter, 30
  5-*epi*-gentamicin, 798
  5-*epi*-sisomicin, 798
  plasmid-mediated production, 30
2″Aminoglycoside nucleotidyltransferase
  adenylates gentamicin, 537
  adenylates kanamycin, 537
  adenylates tobramycin, 537
  Enterobacteriaceae, 537
Aminoglycoside-resistant bacteria
  5-*epi*-gentamicin, 798
  5-*epi*-sisomicin, 798
Aminoglycosides
  multidrug-resistant, gram-negative bacilli, 20
  rifampin, 730
  synergy with penicillin or ampicillin, 359
  testing by microdilution system, 20
  vancomycin, 730
Aminothiazolyl cephalosporin
  Enterobacteriaceae, 807
  GR-20263, 807
  Pseudomonas, 807
Amoxicillin
  absorption and disposition kinetics, 199
  ampicillin-resistant strains, 908
  antibacterial activity, 908
  combined with clavulanic acid, 908
  normal humans, 199
Amoxicillin activity
  human urinary bladder, 554
Amphotericin B
  Candida species, 484
  with rifampin, 484
Ampicillin
  amoxicillin and clavulanic acid, 908
  compared with cefamandole, cephalothin, and chloramphenicol, 37
  compared with cotrimoxazole and chloramphenicol, 43
  dogs, 905
  enteric bacillary meningitis, 406
  experimental *E. coli* meningitis, 37
  fecal flora of dogs, 313
  high dose, 402
  H. influenzae, 80, 461
  H. influenzae type B meningitis, 43
  human urinary bladder, 554
  lactobacilli, 359

low dose, 402
N. denitrificans, 789
pancreatitis, 905
resistant strains, 908
R-plasmids, 313
S. dysenteriae type 1, 402
severe dysentery, 402
synergistically with nafcillin, 461
synergy with aminoglycosides, 359
Ampicillin resistance
shigella, 101
Anaerobic bacteria
agar dilution, 629
carbenicillin, 957
cefamandole, 957
cefoperazone, 957
cefoxitin, 957
chloramphenicol, 957
clindamycin, 957
mecillinam, 954
Anesthetic action
halothane, 890
inhibition of measles virus replication, 890
Anionic liposomes
gentamicin, 544
Antibiotic resistance plasmid
hospital patient flora, 537
Antibiotic susceptibility
beta-lactamase-producing strains, 24
Branhamella (*Neisseria*) *catarrhalis*, 24
Antiherpesviral activity
1-β-D-arabinofuranosyluracil, 1030
Antimicrobial susceptibility
Autobac I, 389
Antimycotic drugs
ketoconazole, 922
sterol synthesis, 922
Antipseudomonal cephalosporin
antibacterial activity, 165
cefsulodin, 165
β-lactamases, 165
1-β-D-Arabinofuranosylthymine
experimental herpes simplex encephalitis, 109
mice, 109
1-β-D-Arabinofuranosyluracil
5-alkenyl derivatives, 1030
antiherpesviral activity, 1030
cell growth, 1030
inhibitory action, 1030
Atrial appendages
cephalosporins, 595
open-heart surgery, 595
Autobac I
antimicrobial susceptibility, 389
contamination levels, 389
Autobac method
MIC, 824
Azlocillin
H. influenzae, 757
impaired renal function, 344
N. gonorrhoeae, 757
normal renal function, 344

Bacitracin
enterococci, 965
Bacterial mutations
gnotoxenic chicken gut system, 327
interbacterial plasmid spreading, 327
Bacteriocin resistance
B. fragilis, 838
Bacteriophage φ6 envelope
protein removal, 1034
retinoids, 1034
Bacterium actinomycetam comitans
susceptibility to 45 antimicrobial agents, 943
Bacteroides fragilis
bacteriocin resistance, 838
beta-lactamase, 1001
cefotaxime, 1001
β-lactamase, 736
metronidazole, 379
newly introduced cephalosporins, 736
rifampin, 838
susceptibility patterns, 686
synergistic antimicrobial combinations, 379
Beagle dogs
lactose-fermenting enteric flora, 428
penicillin, 428
virginiamycin, 428
Beta-lactam antibiotic
1-oxacephalosporin (LY127935), 92
Beta-lactamase
B. fragilis, 1001
cefotaxime, 1001
cephalosporins, 179
coagulase-negative staphylococci, 179
methicillin-resistant staphylococci, 179
methicillin-susceptible staphylococci, 179
minimal effect, 179
Beta-lactamases
antipseudomonal cephalosporin, 165
susceptibility of cefsulodin, 165
Beta-lactam compounds
cephalosporin, 884
GR 20263, 884
Biliary excretion
molecular weight, 842
rats, 842
Binding affinity
E. coli K-12, 316
penicillin-binding proteins, 316
Borinic acid
antibacterial agents, 549
Boron-containing antibacterial agents
bacterial growth and morphology, 549
Branhamella (*Neisseria*) *catarrhalis*
antibiotic susceptibility, 24
beta-lactamase-producing strains, 24
Broth-disk antibiotic susceptibility testing
anaerobic bacteria, 288
vaspar procedure, 288
Broth-disk elution susceptibility test
compared with reference agar dilution method, 740

Cancer chemotherapeutic agents
bioassay of antibiotics in body fluids, 417
cytarabine, 417
dactinomycin, 417

doxorubicin, 417
5-fluorouracil, 417
methotrexate, 417
vinblastine, 417
Cancer patients
Candida spp., 871
gram-negative infections, 1008
mezlocillin, 1008
T. glabrata, 871
Candida
yeast killer toxins, 350
Candidacidal activity
aminoglycoside antibiotics, 87
human neutrophil leukocytes, 87
Candida species
amphotericin B plus rifampin, 484
Candida spp.
cancer patients, 871
miconazole, miconazole nitrate, ketoconazole, and rifampin, 871
Carbenicillin
anaerobic bacteria, 957
420 blood culture isolates, 412
compared with moxalactam (LY127935), 412
compared with piperacillin and ticarcillin, 608
P. aeruginosa, 732
Cation components
gentamicin, 55
Mueller-Hinton agar, 55
P. aeruginosa susceptibility, 55
Cationic liposomes
gentamicin, 544
Cefamandole
anaerobic bacteria, 957
compared with cephalothin, ampicillin, and chloramphenicol, 37
compared with moxalactam (LY127935), 750
E. coli abdominal abscesses, 1023
experimental *E. coli* meningitis, 37
β-lactamase, 179
single doses, 1023
staphylococci, 179
Cefazolin
420 blood culture isolates, 412
compared with ceforanide (BL-S786R), 188
compared with moxalactam (LY127935), 412
E. coli abdominal abscesses, 1023
humans, 188
laboratory animals, 188
β-lactamase, 179
single doses, 1023
staphylococci, 179
Cefoperazone
aerobic gram-negative bacilli, 488
against anaerobic bacteria, 129
against *Enterobacteriaceae*, 423
against *Pseudomonas*, 423
anaerobic bacteria, 957
compared with moxalactam (LY127935), 423
H. influenzae, 757
N. gonorrhoeae, 757
other β-lactam antibiotics, 129
1-oxa-β-lactam (LY127935), 129
Cefoperazone (T-1551)
compared with cephalothin, 743
compared with gentamicin, 743
Ceforanide
cellulitis, 254
end stage renal disease, 251
hemodialysis, 251
Ceforanide (BL-S786R)
compared with cefazolin, 188
humans, 188
laboratory animals, 188
Cefotaxime
aerobic gram-negative bacilli, 488, 937
anaerobic bacteria, 901
anti isomer, 115
B. fragilis, 1001
compared with cefotaxime desacetyl metabolite, 84
compared with ceftizoxime, 397
H. influenzae, 516, 757
hydrolysis, 1001
inhibitory effects, 115
in vitro activity, 937
β-lactamase, 1001
LY127935, 901
N. gonorrhoeae, 757
P. aeruginosa, peptidoglycan biosynthesis, 115
Pseudomonas, 474
syn S-oxide compound, 115
with aminoglycoside, 474
Cefotaxime (HR 756) desacetyl metabolite
activity, 84
compared with cefotaxime, 84
compared with cephalosporins, 84
Cefoxitin
anaerobic bacteria, 957
cerebrospinal fluid, 526
infants and children, 669
parenteral, 669
penetration, 526
probenecid, 847
purulent meningitis, 526
Cefoxitin concentrations
cerebrospinal fluids, 675
meningitis, 675
Cefsulodin
antibacterial activity, 165
antipseudomonal cephalosporin, 165
susceptibility to β-lactamases, 165
Ceftizoxime
dogs, 157
β-lactamase stability, 583
mice, 157
monkeys, 157
parenterally, 157
rats, 157
Ceftizoxime (FK749)
compared with cefotaxime, 397
Cell death
N. meningitidis, 715
penicillin G, 715
Cellulitis
ceforanide, 254
Cephalexin
combined with alafosfalin, 973
humans, 973

Cephalosporin
3-acetoxymethyl, 99
anti-pseudomonal activity, 876
cefoperazone (T-1551), 743
ceftizoxime, 583
GR 20263, 876, 884
hydrolysis, 99
β-lactamase stability, 583
Cephalosporins
B. fragilis, 736
biliary excretion, 842
cefamandole, 179
cefazolin, 179
cephalothin, 179
cephapirin, 179
coagulase-negative staphylococci, 179
β-lactamase, 179, 736
methicillin-resistant *S. aureus*, 856
methicillin-resistant staphylococci, 179
methicillin-susceptible *S. aureus*, 856
methicillin-susceptible staphylococci, 179
molecular weight, 842
rats, 842
Cephalothin
compared with cefamandole, ampicillin, and chloramphenicol, 37
compared with cefoperazone (T-1551), 743
enterococci, 965
experimental *E. coli* meningitis, 37
β-lactamase, 179
staphylococci, 179
Cephamycin C synthesis
L-lysine ε-aminotransferase, 679
S. lactamdurans, 679
Cephapirin
β-lactamase, 179
staphylococci, 179
Cerebrospinal fluid
cefoxitin penetration, 526
experimental meningitis, 286
purulent meningitis, 526
spectinomycin, 286
Cerebrospinal fluids
cefoxitin, 675
meningitis, 675
Chloramphenicol
agar dilution, 629
anaerobic bacteria, 957
compared with ampicillin and cotrimoxazole, 43
compared with cefamandole, cephalothin, and ampicillin, 37
experimental *E. coli* meningitis, 37
fecal flora of dogs, 313
H. influenzae type B meningitis, 43
R-plasmids, 313
Clavulanic acid
ampicillin-resistant strains, 908
combined with amoxicillin, 908
Clindamycin
agar dilution, 629
anaerobic bacteria, 957
penicillinase production, 13
S. aureus, 13
subminimal inhibitory concentrations, 13
Clostridium difficile
antibiotic-associated colitis, 695
antibiotic-associated diarrhea, 695
Colitis
antibiotic-associated, 695
C. difficile, 695
Cotrimoxazole
compared with ampicillin and chloramphenicol, 43
H. influenzae type B meningitis, 43
predictive pharmacokinetics, 132
slow infusions, 132
CP-45,899
against *Bacteroides*, 623
against *H. influenzae*, 623
against penicillin-resistant *Staphylococcus*, 623
combined with ampicillin, 623
combined with penicillin, 623
Cyclacillin
N. gonorrhoeae, 89
single-dose therapy, 89
Cycloserine
enterococci, 965
Cytarabine
bioassay of antibiotics, 417
Cytochrome C_{552}
P. aeruginosa, 71
Cytochrome P-450
type II interferon induction, 969
Cytostatic activity
mammalian cells, 699
polyene macrolides, 699
Cytotoxicity
adriamycin, 443
Saccharomyces uptake, 443

Dactinomycin
bioassay of antibiotics, 417
Dermatophytes
antimycotic susceptibility testing, 725
standardized fragmented mycelial inoculum, 725
testing in microcultures, 725
Diarrhea
antibiotic-associated, 695
C. difficile, 695
Diazaborine
antibacterial agents, 549
Diffusion chambers
ampicillin, 779
azlocillin, 779
cefazolin, 779
gentamicin, 779
rabbits, 779
Dogs
ampicillin excretion, 905
ceftizoxime, 157
pancreatitis, 905
Doxorubicin
bioassay of antibiotics, 417
Drug susceptibility testing
influenza viruses, 865
plaque inhibition assay, 865

(*E*)-5-(2-bromovinyl)-2′-deoxyuridine
experimental herpes simplex keratitis, 8

Eighth-nerve toxicity
amikacin, 707
netilmicin, 707
Endocarditis
rabbits, 280
S. epidermidis, 280
End stage renal disease
ceforanide, 251
Enteric bacillary meningitis
ampicillin, 406
moxalactam (LY127935), 406
netilmicin, 406
Enteric flora
beagle dogs, 428
lactose-fermenting, 428
Enterobacteriaceae
2″aminoglycoside nucleotidyltransferase, 537
aminothiazolyl cephalosporin, 807
cefoperazone, 423
GR-20263, 807
LY127935, 423
Enterococci
bacitracin, 965
cephalothin, 965
cycloserine, 965
penicillin G, 965
vancomycin, 965
Enzyme multiplied immunoassay technique (EMIT)
gentamicin, 776
5-*epi*-Gentamicin
aminoglycoside-modifying enzymes, 798
aminoglycoside-resistant bacteria, 798
5-*epi*-Sisomicin
aminoglycoside-modifying enzymes, 798
aminoglycoside-resistant bacteria, 798
Erythromycin
penicillinase production, 13
S. aureus, 13
subminimal inhibitory concentrations, 13
Escherichia coli abdominal abscesses
cefamandole, 1023
cefazolin, 1023
Escherichia coli K-12
moxalactam (6059-S), 316
penicillin-binding proteins, 316
Ethylenediaminetetraacetic acid
P. aeruginosa, 732
Experimental encephalitis
1-β-D-arabinofuranosylthymine, 109
herpes simplex virus, 109
mice, 109
Experimental *Escherichia coli* meningitis
comparison of cefamandole, cephalothin, ampicillin, and chloramphenicol, 37
Experimental herpes simplex keratitis
(*E*)-5-(2-bromovinyl)-2′-deoxyuridine, 8
Experimental meningitis
cerebrospinal fluid, 286
spectinomycin, 286

Fatty acids
polyene antibiotics, 861
Fecal floras
trimethoprim, 263
trimethoprim-sulfamethoxazole, 263
Fever
modified polyriboinosinic-polyribocytidylic acid complex, 49
rabbits, 49
2′-Fluoro-5-iodo-aracytosine
anti-herpesvirus agent, 803
5-Fluorouracil
bioassay of antibiotics, 417
FP plasmids
P. aeruginosa, 293

Gentamicin
bactericidal activities, 334
bacteriostatic activities, 334
compared with cefoperazone (T-1551), 743
compared with netilmicin, 184
EMIT, 776
humans, 184
β-lactam antibiotics, 334
liposome-associated, 544
low concentrations, 334
plasma β_2 microglobulin, 530
Micromonospora medium extracts, 510
Mueller-Hinton agar, 55
neutral, amionic, and cationic liposomes, 544
P. aeruginosa, 55
preparation and properties, 544
radioimmunoassay, 510
serum concentrations, 530
Gentamicin assay
glucose, 918
heparin, 918
sodium phosphate, 918
Gingival crevice fluid
tetracycline assay, 193
Glycine
P. aeruginosa, 732
Gnotoxenic chicken gut
bacterial mutations, 327
interbacterial plasmid spreading, 327
plasmid mutations, 327
GR-20263
aminothiazolyl cephalosporin, 807
anti-pseudomonal activity, 876
beta-lactam compounds, 884
broad-spectrum cephalosporin, 876
cephalosporin, 884
Enterobacteriaceae, 807
Pseudomonas, 807
Gram-negative bacilli
aerobic, 937
aminoglycosides, testing of, 20
cefoperazone, 488
cefotaxime, 488, 937
LY127935 (1-oxa-β-lactam), 273
moxalactam, 937
moxalactam (LY127935), 488
Group F vibrio
from Bangladesh, 512
R-factor carriage, 512
guanine, 144
mice, 109, 209

Haemophilus ducreyi

β-lactamase production, 897
Haemophilus influenzae
ampicillin, 461, 470
ampicillin-resistant, 461
ampicillin-resistant strain, 80
azlocillin, 757
cefoperazone, 757
cefotaxime, 516, 757
chloramphenicol, 470
CP-45,899 + ampicillin, 623
CP-45,899 + penicillin, 623
in vitro susceptibility, 470
isolation, 80
mezlocillin, 757
moxalactam (LY127935), 470, 516, 757
nafcillin, 461
non-β-lactamase-producing strain, 80
pediatric patients, 470
ticarcillin, 470
Haemophilus influenzae type b meningitis
comparison of cotrimoxazole, ampicillin, and chloramphenicol, 43
experimental, 258
1-oxa-β-lactam (LY127935), 258
Haemophilus species
β-lactamase production, 393
new cephalosporins, 393
Herpes simplex virus
9-(2-hydroxyethoxymethyl) acycloguanosine, 144
acyclovir, 209
1-β-D-arabinofuranosylthymine, 109
BSC1 cells, 1014
chicken embryo fibroblasts, 1014
combination chemotherapy, 558
experimental endocarditis, 109
inhibition of multiplication, 1032
PBN, 63
pokeweed antiviral protein, 1032
tunicamycin, 1014
type 1, 558
type 2, 558
virucidal agent, 63
Herpesvirus
2′-fluoro-5-iodo-aracytosine, 803
High-pressure liquid chromatography
single-dose tobramycin, 649
Household dogs
fecal flora, 313
R-plasmids, 313
HR 109
cefotaxime, 115
Human fibroblasts
acyclovir, 947
Human lymphocyte function
co-trimoxazole in vivo, 322
sulfamethoxazole-trimethoprim, 322
Human neutrophil function
co-trimoxazole in vivo, 322
sulfamethoxazole-trimethoprim, 322
Human neutrophil leukocytes
aminoglycoside antibiotics, 87
candidacidal activity, 87
Hydrolysis
3-acetoxymethyl cephalosporins, 99
lysed whole blood, 99
Hypotension
modified polyriboinosinic-polyribocytidylic acid complex, 49
rabbits, 49

Influenzae A and B
amantadine aerosol, 642
mice, 642
ribavirin aerosol, 642
Influenza viruses
plaque inhibition assay, 865
Interbacterial plasmid spreading
bacterial mutations, 327
gnotoxenic chicken gut system, 327
plasmid mutations, 327
Interferon
type II, 969
cytochrome P-450, 969
mismatched analog poly(rI)·poly[r(C_{12}uracil)n], 988
poly(rI)·poly(rC), 988
poly(rI)·poly(rC) L-lysine, 988
Interferon inducers
antiviral properties, 455
interferon-inducing properties, 455
prostaglandins, 455
Invasive diarrhea
adults, 961
trimethoprim-sulfamethoxazole, 961
versus ampicillin, 961
Isoniazid
electron transport chain in *M. phlei*, 450
M. phlei, 450
nicotinamide adenine dinucleotide regulation, 450
Isoniazid interaction
M. phlei, 170
mycobacteria, 170
tyrosine, 170

Kanamycin
experimental respiratory tract infection, 494
fecal flora of dogs, 313
K. pneumoniae, 494
mice, 494
R-plasmids, 313
Kanamycin B
UK31214, 298
Ketoconazole
antimycotic drug, 922
cancer patients, 871
Candida spp., 871
ergosterol biosynthesis, 922
T. glabrata, 871
with rifampin, 871
Klebsiella pneumoniae DT-S
experimental respiratory tract infection, 494
kanamycin, 494
mice, 494
KW1070
aminoglycoside antibiotic, 138
antibacterial activity, 138
mice, 138

β-Lactam antibiotic
MK0787, 993
β-Lactam antibiotics
bactericidal activities, 334
bacteriostatic activities, 334
gentamicin, 334
H. influenzae, 757
N. gonorrhoeae, 757
β-Lactamase
B. fragilis, 736
newly introduced cephalosporins, 736
nuclear magnetic resonance spectrometric assay, 16
P. cepacia, 355
purification and properties, 355
S. lavendulae, 124
unstable mutation, 124
β-Lactamase production
Haemophilus species, 393
H. ducreyi, 897
inoculum size, 393
new cephalosporins, 393
TEM type, 897
β-Lactamases
resistance to β-lactam antibiotics, 929
urinary tract infections, 929
Lactobacilli
ampicillin and aminoglycosides synergistically, 359
antibiotic tolerance, 359
penicillin and aminoglycosides synergistically, 359
Lactose-fermenting enteric flora
beagle dogs, 428
penicillin, 428
virginiamycin, 428
Light scattering data
MIC, 813
regression analysis, 813
Luciferase assay
gentamicin concentration, 918
LY127935
against anaerobic bacteria, 129
anaerobic bacteria, 901
cefoperazone, 129
compared with cefotaxime, cefoperazone, cefamandole, and ticarcillin, 273
H. influenzae type b meningitis, 258
β-lactam antibiotic, 92
multiply resistant gram-negative bacilli, 273
normal volunteers, 226
other β-lactam antibiotics, 129
1-oxacephalosporin, 92
LY127935 (moxalactam)
aerobic gram-negative bacilli, 488
against *Enterobacteriaceae*, 423
against *Pseudomonas*, 423
420 blood culture isolates, 412
cefoperazone, 423
compared with cefamandole, 750
compared with tobramycin, 750
enteric bacillary meningitis, 406
H. influenzae, 470, 516
in vitro susceptibility, 470
L-Lysine ε-aminotransferase
cephamycin C synthesis, 679
S. lactamdurans, 679
Lysis
N. meningitidis, 715
penicillin G, 715

Measles virus replication
halothane, 890
Mecillinam
anaerobic bacteria, 954
Meningitis
cefoxitin, 675
cerebrospinal fluid, 675
Methicillin
cardiac surgery, 269
Methotrexate
bioassay of antibiotics, 417
5-Methoxymethyldeoxyuridine
combined with adenine arabinoside, 5-ethyldeoxyuridine, 5-iododeoxyuridine, and phosphonoacetic acid, 558
herpes simplex virus types 1 and 2, 558
N^6-methyladenine
trypanosomid flagellates, 567
Metronidazole
B. fragilis, 379
Mezlocillin
cancer patients, 1008
gram-negative infections, 1008
H. influenzae, 757
N. gonorrhoeae, 757
Mezlocillin pharmacokinetics
renal function, 599
single intravenous doses, 599
Mice
ceftizoxime, 157
Miconazole
cancer patients, 871
Candida spp., 871
T. glabrata, 871
with rifampin, 871
Miconazole nitrate
cancer patients, 871
Candida spp., 871
T. glabrata, 871
with rifampin, 871
Microdilution
aminoglycosides, 20
susceptibility testing, 20
Plasma β_2 microglobulin
gentamicin serum concentrations, 530
Micromonospora medium extracts
gentamicin, 510
Minimum inhibitory concentrations
Autobac method, 824
light scattering data, 813
regression analysis, 813
Mismatched analog polyriboinosinic acid·poly[r(C_{12}-uracil)*n*]
inducing interferon, 988
MK0787
evaluation, 993
Monkeys
ceftizoxime, 157
Moxalactam
aerobic gram-negative bacilli, 937

in vitro activity, 937
obstetrical infections, 1004
Moxalactam (LY127935)
aerobic gram-negative bacilli, 488
against *Enterobacteriaceae*, 423
against *Pseudomonas*, 423
anaerobic bacteria, 901
420 blood culture isolates, 412
cefoperazone, 423
cefotaxime, 901
compared with cefamandole, 750
compared with cefazolin, amikacin, tobramycin, 412
carbenicillin, piperacillin, and ticarcillin, 412
compared with tobramycin, 750
enteric bacillary meningitis, 406
H. influenzae, 470, 516, 757
in vitro susceptibility, 470
N. gonorrhoeae, 757
Moxalactam (6059-S)
E. coli K-12, 316
expanded antibacterial spectrum, 302
1-oxa-β-lactam, 302
penicillin-binding proteins, 316
Mueller-Hinton agar
cation components, 55
gentamicin, 55
P. aeruginosa susceptibility, 55
Murein hydrolase
lethal effect, 235
penicillin-treated *S. sanguis*, 235
Mutacin GS-5
mutational loss of sensitivity, 151
receptor protein-deficient mutant, 151
S. pyogenes, 151
Mycelial inoculum
dermatophytes, 725
fragmented, 725
Mycobacteria
isoniazid interaction, 170
M. phlei, 170
tyrosine, 170
Mycobacterium phlei
electron transport chain, 450
isoniazid resistance, 663
isoniazid susceptibility, 663
nicotinamide adenine dinucleotide, 450
nicotinamide adenine dinucleotide glycohydrolase, 663

Nafcillin
H. influenzae, 461
synergistically with ampicillin, 461
Nalidixic acid analog
AM-715, 103
Nalidixic acid derivative
AB206, 763
gram-negative bacteria, 763
Naphthyridine derivative
AB206, 203
Neisseria denitrificans
ampicillin, 789
antibiotic resistance, 789
penicillin-binding proteins, 789
Neisseria gonorrhoeae
azlocillin, 757
cefoperazone, 757
cefotaxime, 757
cyclacillin, 89
mezlocillin, 757
moxalactam (LY127935), 757
single-dose therapy, 89
sulfamethoxazole-trimethoprim, 247
Neisseria meningitidis
cell death, 715
lysis, 715
penicillin G, 715
Neomycin
fecal flora of dogs, 313
R-plasmids, 313
Netilmicin
compared with amikacin, 217
compared with gentamicin, 184
efficacy and toxicity, 217
eighth-nerve toxicity, 707
enteric bacillary meningitis, 406
humans, 184
Neutral liposomes
gentamicin, 544
New cephalosporins
cefoperazone, 393
cefoxitin, 393
cefsulodin, 393
Haemophilus species, 393
moxalactam (LY127935), 393
N-formimidoyl thienamycin
antibacterial activities, 912
N-formimidoyl thienamycin (MK0787)
evaluation, 993
Nicotinamide adenine dinucleotide
electron transport chain, 450
isoniazid, 450
M. phlei, 450
Nicotinamide adenine dinucleotide glycohydrolase
isoniazid-resistant *M. phlei*, 663
isoniazid-susceptible *M. phlei*, 663
Nitrate reductase
P. aeruginosa, 71
Nonmetabolized cephalosporins
atrial appendages, 595
open-heart surgery, 595
pericardial fluids, 595
Nuclear magnetic resonance spectrometric assay
β-lactamase, 16

Obstetrical infections
moxalactam, 1004
1-Oxacephalosporin
β-lactam antibiotic, 92
LY127935, 92
1-Oxacephalosporin (LY127935)
compared with antipseudomonal antimicrobial agents, 96
P. aeruginosa, 96
1-Oxa-β-lactam
compared with cefotaxime, cefoperazone, cefamandole, and ticarcillin, 273
gram-negative bacilli, 273
LY127935, 273

1-Oxa-β-lactam (LY127935)
against anaerobic bacteria, 129
cefoperazone, 129
H. influenzae type b meningitis, 258
normal volunteers, 226
other β-lactam antibiotics, 129
1-Oxa-β-lactam (moxalactam)
expanded antibacterial spectrum, 302
6059-S, 302

Pancreatitis
ampicillin excretion, 905
dogs, 905
Pantomycin
chemical and physical characteristics, 980
S. hygroscopicus, 980
Penicillin
agar dilution, 629
beagle dogs, 428
lactobacilli, 359
lactose-fermenting enteric flora, 428
penicillin-resistant *H. influenzae*, 623
penicillin-resistant *Staphylococcus*, 623
synergy with aminoglycosides, 359
Penicillin-binding proteins
multiple changes, 364
N. denitrificans, 789
S. cacaoi, 1
S. clavuligerus, 1
S. olivaceus, 1
S. pneumoniae, 364, 434
Penicillin G
A. quadruplicatum, 506
enterococci, 965
low concentrations, 715
mesosome-like structures, 506
N. meningitidis, 715
Penicillins
serum dynamics, 229
single, large parenteral doses, 229
subcutaneous chamber fluid dynamics, 229
Peniophora affinis Burt
peniophorin A, 636
peniophorin B, 636
Peniophorin A
P. affinis Burt, 636
structures and antimicrobial activity, 636
Peniophorin B
P. affinis Burt, 636
structures and antimicrobial activity, 636
Peptidoglycan
biosynthesis, 115
inhibitory effects of cefotaxime, its *anti* isomer, and the *syn* S-oxide compound, 115
P. aeruginosa, 115
Peptidoglycan synthesis
inhibition, 572
S. mutans, 572
Pericardial fluids
cephalosporins, 595
open-heart surgery, 595
Periodontal pockets
streptococcal flora, 372
tetracycline, 372
Peripheral blood mononuclear cells
acyclovir, 947
herpesvirus antigens, 947
phytohemagglutinin, 947
Phytoalexins
zoopathogenic fungi, 120
Piperacillin
420 blood culture isolates, 412
compared with moxalactam (LY127935), 412
compared with ticarcillin and carbenicillin, 608
pharmacokinetics, 608
Plaque inhibition assay
influenza viruses, 865
Plasmid-mediated production
Acinetobacter, 30
aminoglycoside-modifying enzymes, 30
Plasmid mutations
gnotoxenic chicken gut system, 327
interbacterial plasmid spreading, 327
Pneumococci
South African strains, 434
S. pneumoniae, 434
Pokeweed antiviral protein
herpes simplex virus, 1032
Polyene antibiotics
fatty acids, 861
Polyene macrolides
cytostatic activity, 699
mammalian cells, 699
potassium efflux induction, 699
Polyriboinosinic·polyribocytidylic acid
inducing interferon, 988
toxicity, 988
Polyriboinosinic-polyribocytidylic acid complex
fever, 49
hypotension, 49
rabbits, 49
serum interferon, 49
Polyriboinosinic·polyribocytidylic acid L-lysine complexed with carboxymethyl cellulose, 988
inducing interferon, 988
Potassium efflux
induction, 699
mammalian cells, 699
polyene macrolides, 699
Pristinamycin
penicillinase production, 13
S. aureus, 13
subminimal inhibitory concentrations, 13
Probenecid
cefoxitin, 847
orally administered, 847
Prostaglandins
interferon inducers, 455
Protein binding
atrial appendages, 595
nonmetabolized cephalosporins, 595
pericardial fluids, 595
Protein synthesis
inhibition, 572
S. mutans, 572
Pseudomonas
aminoglycoside-resistant, 474
aminothiazolyl cephalosporin, 807

cefoperazone, 423
cefotaxime-aminoglycoside, 474
GR-20263, 807
LY127935, 423
Pseudomonas aeruginosa
aminoglycoside-resistant mutation, 71
antipseudomonal antimicrobial agents, 96
carbenicillin, 732
cytochrome C_{552}, 71
ethylenediaminetetraacetic acid, 732
gentamicin, 55
glycine, 732
inhibitory effects of cefotaxime, its *anti* isomer, and the *syn* S-oxide compound, 115
Mueller-Hinton agar, 55
nitrate reductase, 71
1-oxacephalosporin (LY127935), 96
peptidoglycan biosynthesis, 115
R and FP plasmids, 293
Pseudomonas cepacia
β-lactamase, 355
Purine metabolizing enzymes
trypanosomid flagellates, 567

Rabbits
ampicillin, 779
azlocillin, 779
cefazolin, 779
diffusion chambers, 779
gentamicin, 779
Radioimmunoassay
serum vancomycin concentrations, 654
Rats
ceftizoxime, 157
Renal function
azlocillin, 344
mezlocillin, 599
Retinal
bacteriophage φ6 envelope, 1034
virucidal activity, 1034
Retinoids
bacteriophage φ6 envelope, 1034
retinal, 1034
retinol, 1034
virucidal activity, 1034
Retinol
bacteriophage φ6 envelope, 1034
virucidal activity, 1034
R-factor carriage
Bangladesh isolates, 512
group F vibrio, 512
Ribavirin
respiratory syncytial virus, 770
Ribavirin aerosol
influenza A and B, 642
mice, 642
Ribonucleic acid
inhibition, 572
S. mutans, 572
Rifampin
aminoglycosides, 730
B. fragilis, 838
cancer patients, 871
Candida spp., 871
experimental staphylococcal osteomyelitis, 591
rifampin and methicillin, 658
rifampin and trimethoprim, 658
staphylococcal infections, 658
T. glabrata, 871
vancomycin, 730
with miconazole, miconazole nitrate, and ketoconazole, 871
R-plasmids
fecal flora of dogs, 313
P. aeruginosa, 293

Sensititre system
quantitative antimicrobial drug susceptibility testing, 464
Serum dynamics
penicillins, 229
Serum interferon
modified polyriboinosinic-polyribocytidylic acid complex, 49
rabbits, 49
Shigella
antibiotic resistance, 101
Shigella dysenteriae type 1
ampicillin, 402
severe dysentery, 402
Spectinomycin
cerebrospinal fluid, 286
experimental meningitis, 286
penetration, 286
Sporaricin A
amikacin, 337
antimicrobial activity, 337
dibekacin, 337
gentamicin, 337
Staphylococcal infections
rifampin, 658
rifampin and methicillin, 658
rifampin and trimethoprim, 658
rifampin resistance, 658
Staphylococcal osteomyelitis
rifampin, 591
trimethoprim, 591
Staphylococcus aureus
biomass, 856
cephalosporins, 856
clindamycin, 13
erythromycin, 13
methicillin resistance, 856
methicillin susceptibility, 856
penicillinase production, 13
pristinamycin, 13
Staphylococcus epidermidis
antibiotic resistance, 269
cardiac surgery, 269
cefamandole, 280
cephalothin, 280
endocarditis, 280
gentamicin, 280
methicillin, nafcillin, penicillin, cephalothin, cefamandole, streptomycin, gentamicin, 269
nafcillin, 280
rifampin, 280
vancomycin, 280

Streptococcal flora
periodontal pockets, 372
tetracycline, 372
Streptococcus mutans
peptidoglycan synthesis, 572
protein synthesis, 572
ribonucleic acid synthesis, 572
Streptococcus pneumoniae
multiply resistant South African strains, 434
penicillin-binding proteins, 364, 434
penicillin-resistant isolates, 364
Streptococcus pyogenes
mutacin GS-5, 151
receptor protein-deficient mutant, 151
Streptococcus sanguis
murein hydrolase, 235
penicillin-treated, 235
Streptomyces cacaoi
penicillin-binding proteins, 1
Streptomyces clavuligerus
penicillin-binding proteins, 1
Streptomyces fradiae
adenylate nucleotide pool, 519
tylonolide precursors, 519
tylosin-producing, 519
Streptomyces hygroscopicus
pantomycin, 980
Streptomyces lactamdurans
cephamycin C synthesis, 679
L-lysine ε-aminotransferase, 679
Streptomyces lavendulae
β-lactamase production, 124
unstable variants, 124
Streptomyces olivaceus
penicillin-binding proteins, 1
Subcutaneous chamber fluid dynamics
penicillins, 229
Sulfamethoxazole
intrarenal distribution, 383
Sulfamethoxazole-trimethoprim
acute invasive diarrhea, 961
co-trimoxazole in vivo, 322
human lymphocyte function, 322
human neutrophil function, 322
in vitro, 322
N. gonorrhoeae, 247
versus ampicillin, 961
Sulfonamides
fecal flora of dogs, 313
R-plasmids, 313
Susceptibility testing
microdilution testing, 464
sensititre system, 464
Syncytial virus
ribavirin, 770

TEM
H. ducreyi, 897
β-lactamase production, 897
Tetracycline
agar dilution, 629
assay, 193
gingival crevice fluid, 193
peridontal pockets, 372
streptococcal flora, 372
Thienamycin
N-formimidoyl thienamycin, 912
stabilized, 912
Ticarcillin
420 blood culture isolates, 412
compared with moxalactam (LY127935), 412
compared with piperacillin and carbenicillin, 608
fat, 738
muscle, 738
serum, 738
single intravenous injection, 738
Tobramycin
420 blood culture isolates, 412
compared with moxalactam (LY127935), 412, 750
humans, 649
intermittently, 834
intravenously, 834
single-dose disposition, 649
Torulopsis
yeast killer toxins, 350
Torulopsis glabrata
cancer patients, 871
miconazole, miconazole nitrate, ketoconazole, and rifampin, 871
Trimethoprim
drug-resistant fecal floras, 263
drug-resistant vaginal floras, 263
experimental staphylococcal osteomyelitis, 591
intrarenal distribution, 383
Trimethoprim-sulfamethoxazole
drug-resistant fecal floras, 263
drug-resistant vaginal floras, 263
Trypanosomid flagellates
growth and purine metabolizing enzymes, 567
N^6-methyladenine, 567
Tunicamycin
herpes simplex virus, 1014
Tylonolide precursors
biosynthesis, 519
enzymes, 519
S. fradiae, 519
Type II interferon induction
murine cytochrome P-450 drug metabolism system, 969

UK31214
aminoglycoside, 298
kanamycin B derivative, 298
Urinary bladder
amoxicillin and ampicillin, 554
human, 554
Urinary tract infections
β-lactamases, 929
resistance to β-lactam antibiotics, 929

Vaginal floras
trimethoprim, 263
trimethoprim-sulfamethoxazole, 263
Vancomycin
aminoglycosides, 730
bioassay, 730
enterococci, 965
microbiological assay, 654

radioimmunoassay, 654
rifampin, 730
serum concentrations, 654
Vaspar procedure
anaerobic bacteria, 288
broth-disk susceptibility testing, 288
Vinblastine
methotrexate, 417
Virginiamycin
beagle dogs, 428
lactose-fermenting enteric flora, 428
Viridicin
A. viridans, 784
Virucidal agent
herpes simplex virus, 63
hydrophobic, spin-labeled, 63
PBN, 63

Yeast killer toxins
Candida, 350
sensitivity, 350
Torulopsis, 350

Zoopathogenic fungi
susceptibility to phytoalexins, 120

ANTIMICROBIAL AGENTS
AND
CHEMOTHERAPY

VOLUME 17

WASHINGTON, DC 20006

1980

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

VOLUME 17 • 1980

EDITORIAL BOARD

GLADYS L. HOBBY, *Editor-in-Chief* (1980)
Infectious Disease Research Institute, Livingston, N.J.

JOEL G. FLAKS, *Editor* (1981)
University of Pennsylvania, Philadelphia

WALTER D. CELMER, *Editor* (1980)
Pfizer Inc., Groton, Conn.

EDWARD W. HOOK, *Editor* (1981)
University of Virginia, Charlottesville

HERBERT L. ENNIS, *Editor* (1982)
Roche Institute of Molecular Biology, Nutley, N.J.

LEON H. SCHMIDT, *Editor* (1981)
University of Alabama in Birmingham, Birmingham, Ala.

Vincent T. Andriole (1981)
John P. Anhalt (1981)
Donald Armstrong (1980)
Robert Austrian (1980)
Arthur L. Barry (1980)
John E. Bennett (1981)
Lawrence E. Bryan (1982)
Robert E. Brummitt (1982)
D. Buyske (1980)
Yves Chabbert (1980)
Royston C. Clowes (1980)
C. Glenn Cobbs (1980)
Paul S. Cohen (1980)
Naomi Datta (1981)
Julian Davies (1980)
Lawrence E. Day (1980)
R. Gordon Douglas, Jr. (1980)
Theodore Eickhoff (1982)
Arthur English (1980)
David S. Feingold (1981)
Robert Fekety (1981)
Sydney Finegold (1982)
Robert J. Fitzgerald (1980)
Anthony J. Glazko (1981)
Irving H. Goldberg (1982)
Harry Gooder (1982)
Jack Gwaltney (1980)
Robert L. Hamill (1982)
Maurice W. Harmon (1981)
Michael Higgins (1980)
Ronald D. Hinsdill (1982)
Richard Hornick (1980)
L. H. Huang (1982)
Milton Huppert (1980)
George Gee Jackson (1980)
George A. Jacoby, Jr. (1982)
Thomas Jones (1980)
William J. Jusko (1980)
Donald Kaye (1982)
Jerome O. Klein (1982)
Vernon Knight (1980)
George S. Kobayashi (1982)
Jordan Konisky (1980)
Matthew E. Levison (1981)
Friedrich C. Luft (1981)
Joan Lusk (1980)
R. Luthy (1980)
Gerald L. Mandell (1980)
Gerald Medoff (1980)
Barbara Minshew (1982)
S. Mitsuhashi (1980)
Robert C. Moellering, Jr. (1982)
R. B. Morin (1982)
Bernard Moss (1981)
John D. Nelson (1980)
Harold C. Neu (1980)
J. F. Niblack (1980)
T. J. Perun (1980)
Charles A. Plate (1982)
Burton M. Pogell (1981)
K. E. Price (1982)
Paul Quie (1980)
W. H. G. Richards (1980)
Mark H. Richmond (1982)
R. W. Rickards (1980)
Richard Roberts (1982)
Richard Root (1980)
Jon E. Rosenblatt (1982)
Milton R. J. Salton (1981)
Merle Sande (1982)
Jay Sanford (1980)
Arthur K. Saz (1982)
F. C. Sciavolino (1982)
Oldrich K. Sebek (1980)
William M. Shannon (1980)
Jerome J. Schentag (1982)
John C. Sherris (1980)
Charles Shipman, Jr. (1982)
Robert W. Sidwell (1981)
Walter Siegenthaler (1980)
Sigmund S. Socransky (1980)
P. Frederick Sparling (1981)
R. Sutherland (1982)
Vera L. Sutter (1981)
Morton N. Swartz (1982)
Richard B. Sykes (1982)
Ralph Tompsett (1982)
Hamao Umezawa (1981)
Donald Van Harken (1982)
D. Vazquez (1980)
Michael Waring (1981)
John Washington II (1981)
Pamela Waterworth (1982)
Jerry A. Weisbach (1982)
B. Weisblum (1982)
Peter G. Welling (1982)
Richard Wenzel (1980)

Robert A. Day, *Managing Editor*
Gisella Pollock, *Assistant Managing Editor*
Lorraine Gilbert, *Production Editor*
1913 I St., NW, Washington, DC 20006

EX OFFICIO

Willis A. Wood, *President* (1979–1980)
J. Mehsen Joseph, *Secretary*

Albert Balows, *President-Elect* (1979–1980)
Brinton M. Miller, *Treasurer*

Antimicrobial Agents and Chemotherapy (ISSN 0066-4804), an interdisciplinary publication of the American Society for Microbiology, 1913 I St., N.W., Washington, D.C. 20006, is devoted to the dissemination of knowledge relating to all aspects of antimicrobial agents, anticancer agents, and chemotherapy. Instructions to Authors are published in the January issue each year. *Antimicrobial Agents and Chemotherapy* is published monthly, and the twelve numbers are divided into two volumes per year. The nonmember subscription price is $65 per year. The member subscription price is $16 per year. Single copies are $6. Correspondence relating to subscriptions, reprints, defective copies, availability of back issues, lost or late proofs, disposition of submitted manuscripts, and general editorial matters should be directed to the ASM Publications Office, 1913 I St., NW, Washington, DC 20006 (area 202 833-9680).

Second class postage paid at Washington, D.C. 20006, and at additional mailing offices.

Made in the United States of America.

Copyright © 1980, American Society for Microbiology.
All Rights Reserved.

The code at the top of the first page of an article in this journal indicates the copyright owner's consent that copies of the article may be made for personal use, or for personal use of specific clients. This consent is given on the condition, however, that the copier pay the stated per-copy fee through the Copyright Clearance Center, Inc., P.O. Box 765, Schenectady, New York 12301, for copying beyond that permitted by Sections 107 and 108 of the U.S. Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works or for resale.

日本・価格は外貨表示上は関係ない旨記述

Volume 17 Contents for January Number 1

Biosynthesis; Chemistry; Mechanisms of Action and Resistance

Nuclear Magnetic Resonance Spectrometric Assay of β-Lactamase. MEGUMI KONO,* KOJI O'HARA, AND YOKO SHIOMI 16–19

Evidence of Plasmid-Mediated Production of Aminoglycoside-Modifying Enzymes Not Previously Described in *Acinetobacter*. BARBARA E. MURRAY AND ROBERT C. MOELLERING, JR.* 30–36

Studies with a Hydrophobic, Spin-Labeled Virucidal Agent. NEAL DELUCA, ALEC KEITH, AND WALLACE SNIPES* 63–70

Aminoglycoside-Resistant Mutation of *Pseudomonas aeruginosa* Defective in Cytochrome c_{552} and Nitrate Reductase. L. E. BRYAN,* THALIA NICAS, B. W. HOLLOWAY, AND CAROL CROWTHER 71–79

Physiological Effects and Microbial Susceptibility

Penicillin-Binding Proteins of *Streptomyces cacaoi*, *Streptomyces olivaceus*, and *Streptomyces clavuligerus*. HIROSHI OGAWARA* AND SUSUMU HORIKAWA 1–7

Effects of Subminimal Inhibitory Concentrations of Erythromycin, Clindamycin, and Pristinamycin on the Penicillinase Production of *Staphylococcus aureus*. JACQUES MICHEL,* PNINA STESSMAN, AND JOCHANAN STESSMAN 13–15

Evaluation of a Commercial Microdilution System for Quantitative Susceptibility Testing of Aminoglycosides Against Multidrug-Resistant, Gram-Negative Bacilli. LANCE R. PETERSON,* DALE N. GERDING, MARGARET M. JOHNSON, JOHN E. CHERNE, BONNIE J. OPFER, AND WENDELL H. HALL 20–23

Antibiotic Susceptibility of Beta-Lactamase-Producing Strains of *Branhamella* (*Neisseria*) *catarrhalis*. GARY V. DOERN, KATHY G. SIEBERS, LESLEY M. HALLICK, AND STEPHEN A. MORSE* 24–29

Cation Components of Mueller-Hinton Agar Affecting Testing of *Pseudomonas aeruginosa* Susceptibility to Gentamicin. MARGARET A. KENNY, HELEN M. POLLOCK, BARBARA H. MINSHEW, EDMUNDO CASILLAS, AND FRITZ D. SCHOENKNECHT* 55–62

Activity of the Cefotaxime (HR756) Desacetyl Metabolite Compared With Those of Cefotaxime and Other Cephalosporins. R. WISE,* P. J. WILLS, J. M. ANDREWS, AND K. A. BEDFORD 84–86

Inhibition of Candidacidal Activity of Human Neutrophil Leukocytes by Aminoglycoside Antibiotics. FRANCO A. FERRARI, AMBROGIO PAGANI, MASSIMO MARCONI, RENZO STEFANONI, AND ANTONIO G. SICCARDI* 87–88

In Vitro Studies of 1-Oxacephalosporin (LY 127935), a New Beta-Lactam Antibiotic. SUSANNE S. WEAVER, BARBARA M. LEBLANC, AND GERALD P. BODEY* 92–95

Comparative Susceptibilities of *Pseudomonas aeruginosa* to 1-Oxacephalosporin (LY127935) and Eight Other Antipseudomonal Antimicrobial Agents (Old and New). VICTOR L. YU,* RICHARD M. VICKERS, AND JEFFREY J. ZURAVLEFF 96–98

Hydrolysis of 3-Acetoxymethyl Cephalosporins by Lysed Whole Blood. WALTER E. WRIGHT* AND JUDITH A. FROGGE 99–100

* Asterisk refers to person to whom inquiries regarding the paper should be addressed.

Pharmacology and Therapeutics

(*E*)-5-(2-Bromovinyl)-2′-Deoxyuridine in the Treatment of Experimental Herpes Simplex Keratitis. P. C. MAUDGAL, E. DE CLERCQ,* J. DESCAMPS, L. MISSOTTEN, P. DE SOMER, R. BUSSON, H. VANDERHAEGHE, G. VERHELST, R. T. WALKER, AND A. S. JONES 8–12

Comparison of Cefamandole, Cephalothin, Ampicillin, and Chloramphenicol in Experimental *Escherichia coli* Meningitis. THOMAS R. BEAM, JR.,* AND JAMES C. ALLEN 37–42

Comparison of Cotrimoxazole, Ampicillin, and Chloramphenicol in Treatment of Experimental *Haemophilus influenzae* Type B Meningitis. JOHN R. PERFECT, SELWYN D. R. LANG, AND DAVID T. DURACK* 43–48

Modified Polyriboinosinic-Polyribocytidylic Acid Complex: Induction of Serum Interferon, Fever, and Hypotension in Rabbits. BIENVENIDO G. GATMAITAN, REUBEN C. LEGASPI, HILTON B. LEVY, AND A. MARTIN LERNER* 49–54

Isolation of an Ampicillin-Resistant, Non-β-Lactamase-Producing Strain of *Haemophilus influenzae*. SHELDON M. MARKOWITZ 80–83

Pharmacological and In Vitro Evaluation of Cyclacillin: Assessment as Potential Single-Dose Therapy for Treatment of *Neisseria gonorrhoeae* Infection. KENNETH F. WAGNER, ANDREW D. BLAIR, GEORGE W. COUNTS, AND KING K. HOLMES* 89–91

Rise and Fall of Shigella Antibiotic Resistance. PHILIP W. MEYER AND STEPHEN J. LERMAN* 101–102

Volume 17 Contents for February Number 2

Biosynthesis; Chemistry; Mechanisms of Action and Resistance

Biosynthesis of Peptidoglycan in *Pseudomonas aeruginosa*: Comparison of the Inhibitory Effects of Cefotaxime, Its *Anti* Isomer, and the *Syn* S-Oxide Compound. DAVID MIRELMAN* AND YAEL NUCHAMOWITZ 115–119

Unstable Mutation of β-Lactamase Production in *Streptomyces lavendulae*. MICHIKO MATSUBARA-NAKANO,* YOKO KATAOKA, AND HIROSHI OGAWARA 124–128

Mutational Loss of Sensitivity to Mutacin GS-5 in *Streptococcus pyogenes*: Characterization of a Mutant Deficient in Receptor Protein. COLIN K. FRANKER 151–156

Isoniazid Interaction with Tyrosine as a Possible Mode of Action of the Drug in Mycobacteria. R. PETER HERMAN AND MORTON M. WEBER* 170–178

Pathogenicity in Mice of Strains of Herpes Simplex Virus Which are Resistant to Acyclovir In Vitro and In Vivo. HUGH J. FIELD* AND GRAHAM DARBY 209–216

Lethal Effect of a Heterologous Murein Hydrolase on Penicillin-Treated *Streptococcus sanguis*. DIANE HORNE* AND ALEXANDER TOMASZ 235–246

Physiological Effects and Microbial Susceptibility

In Vitro Antibacterial Activity of AM-715, a New Nalidixic Acid Analog. AKIRA ITO,* KEIJI HIRAI, MATSUHISA INOUE, HIROSHI KOGA, SEIGO SUZUE, TSUTOMU IRIKURA, AND SUSUMU MITSUHASHI 103–108

Susceptibility of Zoopathogenic Fungi to Phytoalexins. MORRIS A. GORDON,* EDWARD W. LAPA, MINDY S. FITTER, AND MARJORIE LINDSAY 120–123

Comparative In Vitro Activity of 1-Oxa-β-Lactam (LY127935) and Cefoperazone with Other β-Lactam Antibiotics Against Anaerobic Bacteria. M. VICTORIA BOROBIO, JAVIER AZNAR, RUFINO JIMENEZ, FERNANDO GARCIA, AND EVELIO J. PEREA* 129–131

In Vitro and In Vivo Antibacterial Activity of KW1070, a New Aminoglycoside Antibiotic. YOICHI OHASHI, HARUHIDE KAWABE, KIYOSHI SATO, NOBUO NAKAMURA, SATONORI KURASHIGE, AND SUSUMU MITSUHASHI* 138–143

In Vitro and In Vivo Resistance of Herpes Simplex Virus to 9-(2-Hydroxyethoxymethyl)guanine (Acycloguanosine). KENDALL O. SMITH,* WIEBKE L. KENNELL, ROBERT H. POIRIER, AND FREDERICK T. LYND 144–150

In Vitro Antibacterial Activity and Susceptibility of Cefsulodin, an Antipseudomonal Cephalosporin, to Beta-Lactamases. ANNA KING, KEVIN SHANNON, AND IAN PHILLIPS* 165–169

Activity of Cephalosporins Against Methicillin-Susceptible and Methicillin-Resistant, Coagulase-Negative Staphylococci: Minimal Effect of Beta-Lactamase. JOSEPH F. JOHN, JR.,* AND WILLIAM F. MCNEILL 179–183

Sensitive Assay for Measuring Tetracycline Levels in Gingival Crevice Fluid. JEFFREY M. GORDON,* CLAY B. WALKER, J. MAX GOODSON, AND SIGMUND S. SOCRANSKY 193–198

Sulfamethoxazole-Trimethoprim Synergism Against *Neisseria gonorrhoeae*. MICHAEL F. REIN,* W. CLAYTON ELLIOTT, JANA M. SWENSON, AND CLYDE THORNSBERRY 247–250

Comparative Activities of the Oxa-β-Lactam LY127935, Cefotaxime, Cefoperazone, Cefamandole, and Ticarcillin Against Multiply Resistant Gram-Negative Bacilli. WENDELL H. HALL,* BONNIE J. OPFER, AND DALE N. GERDING 273–279

Vaspar Broth-Disk Procedure for Antibiotic Susceptibility Testing of Anaerobic Bacteria. SUSAN E. H. WEST AND TRACY D. WILKINS* 288–291

Pharmacology and Therapeutics

Effect of Treatment with 1-β-D-Arabinofuranosylthymine of Experimental Encephalitis Induced by Herpes Simplex Virus in Mice. HARUHIKO MACHIDA,* MASATSUNE ICHIKAWA, AKIRA KUNINAKA, MINEO SANEYOSHI, AND HIROSHI YOSHINO 109–114

Evaluation of Slow Infusions of Co-Trimoxazole by Using Predictive Pharmacokinetics. DENIS J. MORGAN* AND KENNETH RAYMOND 132–137

Pharmacokinetics of Ceftizoxime in Animals After Parenteral Dosing. TAKEO MURAKAWA, HIROSHI SAKAMOTO, SHIGEMI FUKADA, SHOJI NAKAMOTO, TOSHIHARU HIROSE, NORIKAZU ITO, AND MINORU NISHIDA* 157–164

Comparison of Netilmicin and Gentamicin Pharmacokinetics in Humans. MENGER CHUNG,* ROBERT COSTELLO, AND SAMSON SYMCHOWICZ 184–187

Comparative Pharmacokinetics of Ceforanide (BL-S786R) and Cefazolin in Laboratory Animals and Humans. FRANCIS H. LEE, MORRIS PFEFFER, DONALD P. VAN HARKEN, ROBERT D. SMYTH,* AND GIRARD H. HOTTENDORF 188–192

Absorption and Disposition Kinetics of Amoxicillin in Normal Human Subjects. A. ARANCIBIA,* J. GUTTMANN, G. GONZÁLEZ, AND C. GONZÁLEZ 199–202

In Vitro and In Vivo Antibacterial Activity of AB206, a New Naphthyridine Derivative. TAKATOSHI NAGATE,* SATONORI KURASHIGE, AND SUSUMU MITSUHASHI 203–208

Prospective Comparative Study of Efficacy and Toxicity of Netilmicin and Amikacin. BONNIE V. BOCK, PAUL H. EDELSTEIN, AND RICHARD D. MEYER* 217–225

Pharmacology of a New 1-Oxa-β-Lactam (LY127935) in Normal Volunteers. JAMES N. PARSONS, JOSEPH M. ROMANO, AND MATTHEW E. LEVISON* 226–228

Serum and Subcutaneous Chamber Fluid Dynamics of Penicillins After Single Large Parenteral Doses. ROBERT R. TIGHT* AND ARTHUR C. WHITE 229–234

Pharmacokinetics of Ceforanide in Patients with End Stage Renal Disease on Hemodialysis. JOHN R. HESS, STEVEN J. BERMAN,* WILLIAM BOUGHTON, JARED G. SUGIHARA, JAMES E. MUSGRAVE, EUGENE G. C. WONG, AND ARNOLD M. SIEMSEN 251–253

Treatment of Cellulitis with Ceforanide. DANIEL M. MUSHER,* VICTOR FAINSTEIN, AND EDWARD J. YOUNG 254–257

Treatment of Experimental *Haemophilus influenzae* Type b Meningitis with 1-Oxa-β-Lactam (LY127935). CYNTHIA S. CORDERA AND ROBERT S. PEKAREK* 258–262

Effect of Trimethoprim and Trimethoporim-Sulfamethoxazole on Development of Drug-Resistant Vaginal and Fecal Floras. STEPHEN J. PANCOAST, DAVID M. HYAMS, AND HAROLD C. NEU* 263–268

Antibiotic-Resistant *Staphylococcus epidermidis* in Patients Undergoing Cardiac Surgery. GORDON L. ARCHER* AND MARVIN J. TENEBAUM 269–272

Antibiotic Therapy of Experimental *Staphylococcus epidermidis* Endocarditis. GUILLERMO J. VAZQUEZ AND GORDON L. ARCHER* 280–285

Penetration of Spectinomycin into Cerebrospinal Fluid During Experimental Meningitis. DENNIS G. DELGADO, CARMEN J. BRAU, AND C. KIRK AVENT* 286–287

Volume 17

Contents for March

Number 3

Biosynthesis; Chemistry; Mechanisms of Action and Resistance

Relationship Between R and FP Plasmids in *Pseudomonas aeruginosa*. PAMELA L. ROYLE AND BRUCE W. HOLLOWAY* 293–297

Moxalactam (6059-S), a New 1-Oxa-β-Lactam: Binding Affinity for Penicillin-Binding Proteins of *Escherichia coli* K-12. YOSHIHIDE KOMATSU* AND TOHRU NISHIKAWA 316–321

Parameters Controlling Interbacterial Plasmid Spreading in a Gnotoxenic Chicken Gut System: Influence of Plasmid and Bacterial Mutations. PHILIPPE SANSONETTI, JEAN-PIERRE LAFONT,* ALINE JAFFÉ-BRACHET, JEAN-FRANÇOIS GUILLOT, AND ELISABETH CHASLUS-DANCLA 327–333

Purification and Properties of a New β-Lactamase from *Pseudomonas cepacia*. K. HIRAI,* S. IYOBE, M. INOUE, AND S. MITSUHASHI 355–358

Multiple Changes of Penicillin-Binding Proteins in Penicillin-Resistant Clinical Isolates of *Streptococcus pneumoniae*. REGINE HAKENBECK, MARTHA TARPAY, AND ALEXANDER TOMASZ* ... 364–371

Penicillin-Binding Proteins of Multiply Antibiotic-Resistant South African Strains of *Streptococcus pneumoniae*. SONIA ZIGHELBOIM AND ALEXANDER TOMASZ* ... 434–442

Resistance to Adriamycin Cytotoxicity Among Respiratory-Deficient Mutants. SHARON C. HIXON,* ADIL OCAK, JONAH E. THOMAS, AND J. PATRICK DAUGHERTY ... 443–449

Site of Action of Isoniazid on the Electron Transport Chain and Its Relationship to Nicotinamide Adenine Dinucleotide Regulation in *Mycobacterium phlei*. R. PETER HERMAN AND MORTON M. WEBER* ... 450–454

Physiological Effects and Microbial Susceptibility

UK31214: a New Aminoglycoside and Derivative of Kanamycin B. R. WISE,* J. M. ANDREWS, AND K. A. BEDFORD ... 298–301

Moxalactam (6059-S), a Novel 1-Oxa-β-Lactam with an Expanded Antibacterial Spectrum: Laboratory Evaluation. TADASHI YOSHIDA,* SHINZŌ MATSUURA, MIKAO MAYAMA, YASUO KAMEDA, AND SHŌGO KUWAHARA ... 302–312

Incidence of R-Plasmids in Fecal Flora of Healthy Household Dogs. DWIGHT C. HIRSCH,* GERALD V. LING, AND ANNETTE L. RUBY ... 313–315

Effects of Sulfamethoxazole and Trimethoprim on Human Neutrophil and Lymphocyte Functions In Vitro: In Vivo Effects of Co-Trimoxazole. R. ANDERSON,* GISELA GRABOW, ROBYN OOSTHUIZEN, ANNETTE THERON, AND A. J. VAN RENSBURG ... 322–326

Bacteriostatic and Bactericidal Activities of β-Lactam Antibiotics Enhanced by the Addition of Low Concentrations of Gentamicin. GOHTA MASUDA,* KISHIO NAKAMURA, TARO YAJIMA, AND KAZUE SAKU ... 334–336

High Incidence of Sensitivity to Yeast Killer Toxins Among *Candida* and *Torulopsis* Isolates of Human Origin. EVERT J. MIDDELBEEK,* JOHN M. H. HERMANS, CLAUDIAS STUMM, AND HARRY L. MUYTJENS ... 350–354

Bactericidal Synergy Between Penicillin or Ampicillin and Aminoglycosides Against Antibiotic-Tolerant Lactobacilli. ARNOLD S. BAYER,* ANTHONY W. CHOW, JOAN O. MORRISON, AND LUCIEN B. GUZE ... 359–363

Potentially Synergistic Antimicrobial Combinations with Metronidazole Against *Bacteroides fragilis*. EDWARD D. RALPH* AND YURI E. AMATNIEKS ... 379–382

Effect of Contamination Levels on Antimicrobial Susceptibilities Tested by Autobac I. AZRA SHAHIDI* AND IRENE CHOEY ... 389–392

Effect of Inoculum Size and β-Lactamase Production on In Vitro Activity of New Cephalosporins Against *Haemophilus* Species. ROBERT R. BULGER AND JOHN A. WASHINGTON II* ... 393–396

Comparative In Vitro Activities of Cefotaxime and Ceftizoxime (FK749): New Cephalosporins with Exceptional Potency. DAVID GREENWOOD,* NEIL PEARSON, ADRIAN ELEY, AND FRANCIS O'GRADY ... 397–401

Comparison of In Vitro Activity of Moxalactam (LY127935) with Cefazolin, Amikacin, Tobramycin, Carbenicillin, Piperacillin, and Ticarcillin Against 420 Blood Culture Isolates. LARRY G. REIMER,* STANLEY MIRRETT, AND L. BARTH RELLER ... 412–416

Bioassay of Antibiotics in Body Fluids from Patients Receiving Cancer Chemotherapeutic Agents. DONALD N. WRIGHT* AND JOHN M. MATSEN 417–422

In Vitro Evaluation of Cefoperazone. ANNE M. HINKLE, BARBARA M. LEBLANC, AND GERALD P. BODEY* 423–427

Effect of Penicillin and Virginiamycin on Drug Resistance in Lactose-Fermenting Enteric Flora. STUART A. GAINES,* LARRY D. ROLLINS, ROBERT D. WILLIAMS, AND MURRAY SELWYN 428–433

Antiviral and Interferon-Inducing Properties of Interferon Inducers Administered with Prostaglandins. DALE A. STRINGFELLOW 455–460

Evaluation of the Sensititre System for Quantitative Antimicrobial Drug Susceptibility Testing: a Collaborative Study. T. L. GAVAN,* R. N. JONES, AND A. L. BARRY 464–469

In Vitro Susceptibility of 104 Clinical Isolates of *Haemophilus influenzae* to Moxalactam (LY127935), Ampicillin, Chloramphenicol, and Ticarcillin. EDWARD O. MASON, JR.,* SHELDON L. KAPLAN, DONALD C. ANDERSON, DAVID B. HINDS, AND RALPH D. FEIGIN 470–473

Activity of Cefotaxime-Aminoglycoside Combinations Against Aminoglycoside-Resistant *Pseudomonas*. PATRICK R. MURRAY 474–476

Combined Effect of Amphotericin B and Rifampin on *Candida* Species. JOHN E. EDWARDS, JR.,* JOAN MORRISON, DAVID K. HENDERSON, AND JOHN Z. MONTGOMERIE 484–487

Comparison of Cefoperazone, Cefotaxime, and Moxalactam (LY127935) Against Aerobic Gram-Negative Bacilli. SELWYN D. R. LANG,* DEBORAH J. EDWARDS, AND DAVID T. DURACK 488–493

Effects of Penicillin G on Mesosome-Like Structures in *Agmenellum quadruplicatum*. D. L. BALKWILL AND S. E. STEVENS, JR.* 506–509

Radioimmunoassay of Gentamicin in *Micromonospora* Medium Extracts. ARIE ROSNER* AND HAIM AVIV 510–511

R-Factor Carriage in a Group F Vibrio Isolated from Bangladesh. L. A. MCNICOL, J. B. KAPER, H. A. LOCKMAN, E. F. REMMERS, W. M. SPIRA, M. J. VOLL, AND R. R. COLWELL* 512–515

In Vitro Activities of Cefotaxime and Moxalactam (LY127935) Against *Haemophilus influenzae*. JAMES H. JORGENSEN,* SHARON A. CRAWFORD, AND GARY A. ALEXANDER 516–517

Pharmacology and Therapeutics

In Vitro and In Vivo Antimicrobial Activities of Sporaricin A, a New Aminoglycoside. FUJIO KOBAYASHI,* YUSHI SAINO, TOMOYUKI KOSHI, AND YUKIO HATTORI 337–343

Pharmacokinetics of Azlocillin in Subjects with Normal and Impaired Renal Function. A. LEROY,* G. HUMBERT, M. GODIN, AND J. P. FILLASTRE 344–349

Effects of Tetracycline on the Streptococcal Flora of Periodontal Pockets. ROBERT J. HAWLEY, LINDA N. LEE, AND DONALD J. LEBLANC* 372–378

Intrarenal Distribution of Trimethoprim and Sulfamethoxazole. SYLVIE TROTTIER, MICHEL G. BERGERON,* AND CELINE LESSARD 383–388

Randomized Trial of High- and Low-Dose Ampicillin Therapy for Treatment of Severe Dysentery Due to *Shigella dysenteriae* Type 1. R. H. GILMAN,* F. KOSTER, S. ISLAM, J. MCLAUGHLIN, AND M. M. RAHAMAN 402–405

Pharmacokinetics and Bacteriological Efficacy of Moxalactam (LY127935), Netilmicin, and Ampicillin in Experimental Gram-Negative Enteric Bacillary Meningitis. URS B. SCHAAD, GEORGE H. MCCRACKEN, JR.,* CHRISTINE A. LOOCK, AND MARION L. THOMAS 406–411

Synergistic Action of Ampicillin and Nafcillin Against Ampicillin-Resistant *Haemophilus influenzae*. RAM YOGEV,* ERNEST BURKHOLDER, AND A TODD DAVIS 461–463

Isolation of Drug-Resistant *Aeromonas hydrophila* from Aquatic Environments. LORE ANN MCNICOL, K. M. S. AZIZ, IMDADUL HUQ, JAMES B. KAPER, HANK A. LOCKMAN, ELAINE F. REMMERS, WILLIAM M. SPIRA, MARY J. VOLL, AND RITA R. COLWELL* 477–483

Experimental Respiratory Tract Infection with *Klebsiella pneumoniae* DT-S in Mice: Chemotherapy with Kanamycin. TAKESHI NISHI AND KANJI TSUCHIYA* 494–505

Volume 17 **Contents for April** **Number 4**

Biosynthesis; Chemistry; Mechanisms of Action and Resistance

Metabolic Regulation in Tylosin-Producing *Streptomyces fradiae*: Regulatory Role of Adenylate Nucleotide Pool and Enzymes Involved in Biosynthesis of Tylonolide Precursors. K. VU-TRONG, S. BHUWAPATHANAPUN, AND P. P. GRAY* 519–525

Dissemination of an Antibiotic Resistance Plasmid in Hospital Patient Flora. THOMAS F. O'BRIEN,* DONALD G. ROSS, MANUEL A. GUZMAN, ANTONE A. MEDEIROS, R. W. HEDGES, AND DAVID BOTSTEIN 537–543

Boron-Containing Antibacterial Agents: Effects on Growth and Morphology of Bacteria Under Various Culture Conditions. P. J. BAILEY, G. COUSINS, G. A. SNOW,* AND A. J. WHITE 549–553

Combination Chemotherapy: Interaction of 5-Methoxymethyldeoxyuridine with Adenine Arabinoside, 5-Ethyldeoxyuridine, 5-Iododeoxyuridine, and Phosphonoacetic Acid Against Herpes Simplex Virus Types 1 and 2. NANNA K. AYISI, V. SAGAR GUPTA,* J. BLAIR MELDRUM, ASHOK K. TANEJA, AND LORNE A. BABIUK 558–566

Inhibition of Growth and Purine-Metabolizing Enzymes of Trypanosomid Flagellates by N^6-Methyladenine. LINDA L. NOLAN AND GEORGE W. KIDDER* 567–571

Inhibition of Peptidoglycan, Ribonucleic Acid, and Protein Synthesis in Tolerant Strains of *Streptococcus mutans*. MYRON MYCHAJLONKA, THOMAS D. MCDOWELL, AND GERALD D. SHOCKMAN* 572–582

Effects of Carbon Sources on Chemical Composition of Cell Envelopes of *Pseudomonas aeruginosa* in Association with Polymyxin Resistance. H. E. GILLELAND, JR.,* AND ROBERT S. CONRAD 623–628

Structures and Antimicrobial Activity of Peniophorin A and B, Two Polyacetylenic Antibiotics from *Peniophora affinis* Burt. NANCY N. GERBER, S. AKRAM SHAW, AND H. A. LECHEVALIER* 636–641

Identification of a Nicotinamide Adenine Dinucleotide Glycohydrolase and an Associated Inhibitor in Isoniazid-Susceptible and -Resistant *Mycobacterium phlei*. WILLIAM B. DAVIS 663–668

L-Lysine ε-Aminotransferase Involved in Cephamycin C Synthesis in *Streptomyces lactamdurans*. BRIAN A. KERN, DAVID HENDLIN, AND EDWARD INAMINE* ... 679–685

Dissociation Between the Induction of Potassium Efflux and Cytostatic Activity of Polyene Macrolides in Mammalian Cells. BARBARA MALEWICZ, HOWARD M. JENKIN,* AND EDWARD BOROWSKI ... 699–706

Events Leading to Cell Death and Lysis of *Neisseria meningitidis* in Low Concentrations of Penicillin G. L. G. NEIRINCK, I. W. DEVOE,* AND J. M. INGRAM ... 715–724

Activity of β-Lactamase Produced by *Bacteroides fragilis* Against Newly Introduced Cephalosporins. KENICHI SATO,* MATSUHISA INOUE, AND SUSUMU MITSUHASHI ... 736–737

Physiological Effects and Microbial Susceptibility

Preparation and Properties of Liposome-Associated Gentamicin. JOHN R. MORGAN* AND KEITH E. WILLIAMS ... 544–548

Antibacterial Activity of Ceftizoxime, a β-Lactamase-Stable Cephalosporin. KWUNG P. FU AND HAROLD C. NEU* ... 583–590

Antimicrobial Susceptibility of *Aeromonas hydrophila*. TIMOTHY L. OVERMAN ... 612–614

CP-45,899 in Combination with Penicillin or Ampicillin Against Penicillin-Resistant *Staphylococcus*, *Haemophilus influenzae*, and *Bacteroides*. J. A. RETSEMA,* A. R. ENGLISH, AND A. E. GIRARD ... 615–622

Susceptibility Testing of Clinically Isolated Anaerobic Bacteria by an Agar Dilution Technique. WILLIAM J. BROWN* AND PRISCILLA E. WAATTI ... 629–635

Comparison of a Radioimmunoassay and a Microbiological Assay for Measurement of Serum Vancomycin Concentrations. KENT B. CROSSLEY,* JOHN C. ROTSCHAFER, M. MYRA CHERN, KAREN E. MEAD, AND DARWIN E. ZASKE ... 654–657

Variation in Susceptibility Patterns of Species Within the *Bacteroides fragilis* Group. SHARON L. HANSEN ... 686–690

In Vitro Susceptibility of *Clostridium difficile* Isolates from Patients with Antibiotic-Associated Diarrhea or Colitis. JOANNE DZINK* AND JOHN G. BARTLETT ... 695–698

Antimycotic Susceptibility Testing of Dermatophytes in Microcultures with a Standardized Fragmented Mycelial Inoculum. TIMOTHY C. GRANADE AND WILLIAM M. ARTIS* ... 725–729

Bioassay for Determination of Vancomycin in the Presence of Rifampin or Aminoglycosides. CYNTHIA NEEDHAM WALKER ... 730–731

In Vitro Susceptibility of *Pseudomonas aeruginosa* to Carbenicillin, Glycine, and Ethylenediaminetetraacetic Acid Combinations. G. FRANKLIN GERBERICK* AND PETER A. CASTRIC ... 732–735

Practical Anaerobic Broth-Disk Elution Susceptibility Test. JAMES H. JORGENSEN,* GARY A. ALEXANDER, AND JAMES E. JOHNSON 740–742

Cefoperazone (T-1551), a New Semisynthetic Cephalosporin: Comparison with Cephalothin and Gentamicin. R. N. JONES,* P. C. FUCHS, A. L. BARRY, T. L. GAVAN, H. M. SOMMERS, AND E. H. GERLACH ... 743–749

Moxalactam (LY127935), a New Semisynthetic 1-Oxa-β-Lactam Antibiotic with Remarkable Antimicrobial Activity: In Vitro Comparison with Cefamandole and Tobramycin. RONALD N.

JONES,* PETER C. FUCHS, HERBERT M. SOMMERS, THOMAS L. GAVAN, ARTHUR L. BARRY, AND E. HUGH GERLACH 750–756

In Vitro Antimicrobial Activity of Cefoperazone, Cefotaxime, Moxalactam (LY127935), Azlocillin, Mezlocillin, and Other β-Lactam Antibiotics Against *Neisseria gonorrhoeae* and *Haemophilus influenzae*, Including β-Lactamase-Producing Strains. CAROLYN N. BAKER, CLYDE THORNSBERRY,* AND RONALD N. JONES 757–761

Pharmacology and Therapeutics

Cefoxitin Penetration into Cerebrospinal Fluid in Patients with Purulent Meningitis. PAULO A. AYROSA GALVAO, ANDRÉ VILLELA LOMAR, WALDEMAR FRANCISCO, CID V. FRANCO DE GODOY, AND RAGNAR NORRBY* 526–529

Plasma β_2 Microglobulin as a Means of Predicting Gentamicin Serum Concentrations. J. VALSAMIS,* H. BRAUMAN, AND E. YOURASSOWSKY 530–536

Comparison of Amoxicillin and Ampicillin Activities in a Continuous Culture Model of the Human Urinary Bladder. J. D. ANDERSON,* K. R. JOHNSON, AND M. Y. AIRD 554–557

Treatment of Experimental Staphylococcal Osteomyelitis with Rifampin and Trimethoprim, Alone and Combination. CARL W. NORDEN* AND EVA KELETI 591–594

Effect of Protein Binding on the Penetration of Nonmetabolized Cephalosporins into Atrial Appendages and Pericardial Fluids in Open-Heart Surgical Patients. CHARLES H. NIGHTINGALE, JOSEPH J. KLIMEK, AND RICHARD QUINTILIANI* 595–598

Mezlocillin Pharmacokinetics After Single Intravenous Doses to Patients with Varying Degrees of Renal Function. NIELS FRIMODT-MÖLLER, SVEN MAIGAARD, ROGER D. TOOTHAKER, ROBERT W. BUNDTZEN, MITCHELL V. BRODEY, WILLIAM A. CRAIG, PETER G. WELLING,* AND PAUL O. MADSEN 599–607

Comparative Study of Piperacillin, Ticarcillin, and Carbenicillin Pharmacokinetics. BURT R. MEYERS, SHALOM Z. HIRSCHMAN,* LUCIA STROUGO, AND ELINA SRULEVITCH 608–611

Amantadine and Ribavirin Aerosol Treatment of Influenza A and B Infection in Mice. SAMUEL Z. WILSON, VERNON KNIGHT,* PHILIP R. WYDE, STEPHANIE DRAKE, AND ROBERT B. COUCH 642–648

High-Pressure Liquid Chromatography Analysis and Single-Dose Disposition of Tobramycin in Human Volunteers. DAVID B. HAUGHEY, DAVID M. JANICKE, MARTIN ADELMAN, AND JEROME J. SCHENTAG* 649–653

Treatment of Experimental Staphylococcal Infections: Effect of Rifampin Alone and in Combination on Development of Rifampin Resistance. GERALD L. MANDELL* AND DAVID R. MOORMAN 658–662

Clinical and Pharmacokinetic Evaluation of Parenteral Cefoxitin in Infants and Children. WILLIAM E. FELDMAN,* STEVEN MOFFITT, AND NANCY SPROW 669–674

Cefoxitin Concentrations in the Cerebrospinal Fluids of Patients with Meningitis. GUY HUMBERT, ANNIE LEROY, JEAN-PAUL ROGEZ, AND CHARLES CHERUBIN* 675–678

Pharmacokinetics of Nafcillin in Infants with Low Birth Weights. WILLIAM BANNER, JR., W. MANFORD GOOCH III,* GILBERT BURCKART, AND SHELDON B. KORONES 691–694

Prospective, Randomized Trial of Netilmicin and Amikacin, with

Emphasis on Eighth-Nerve Toxicity. MICHAEL BARZA,* MICHAEL W. LAUERMANN, FRANCIS P. TALLY, AND SHERWOOD L. GORBACH 707–714

Ticarcillin Concentrations in Serum, Muscle, and Fat After a Single Intravenous Injection. F. D. DASCHNER,* G. THOMA, H. LANGMAACK, AND A. DALHOFF 738–739

Volume 17

Contents for May

Number 5

Biosynthesis; Chemistry; Mechanisms of Action and Resistance

Mode of Action of a New Nalidixic Acid Derivative, AB206. TAKATOSHI NAGATE,* TOSHIAKI KOMATSU, AKIO IZAWA, SADABUMI OHMURA, SINJURO NAMIKI, AND SUSUMU MITSUHASHI 763–769

Antibiotic Resistance in *Neisseria denitrificans*. C. R. MACKENZIE, I. J. MCDONALD, AND K. G. JOHNSON* 789–797

5-*epi*-Sisomicin and 5-*epi*-Gentamicin B: Substrates for Aminoglycoside-Modifying Enzymes That Retain Activity Against Aminoglycoside-Resistant Bacteria. A. PAUL VASTOLA, JOELLEN ALTSCHAEFL, AND S. HARFORD* 798–802

2′-Fluoro-5-Iodo-Aracytosine, a Potent and Selective Anti-Herpesvirus Agent. C. LOPEZ,* K. A. WATANABE, AND J. J. FOX 803–806

Rifampin and Bacteriocin Resistance in *Bacteroides fragilis*. KEVIN G. MOSSIE, DAVID T. JONES, FRANK T. ROBB, AND DAVID R. WOODS* 838–841

TEM-Type β-Lactamase Production in *Haemophilus ducreyi*. IAN W. MACLEAN, GEORGE H. W. BOWDEN, AND WILLIAM L. ALBRITTON* 897–900

Effect of Fatty Acids on Action of Polyene Antibiotics. ROBERT C. IANNITELLI AND MIYOSHI IKAWA* 861–864

Anesthetic Action and Virus Replication: Inhibition of Measles Virus Replication in Cells Exposed to Halothane. PAUL R. KNIGHT,* MICHAEL L. NAHRWOLD, AND ELLIOTT BEDOWS 890–896

Physiological Effects and Microbial Susceptibility

Effects of Ribavirin on Respiratory Syncytial Virus in Vitro. JEROME F. HRUSKA,* JACK M. BERNSTEIN, R. GORDON DOUGLAS, JR., AND CAROLINE B. HALL 770–775

Purifications of the Viridicin Produced by *Aerococcus viridans*. J. M. BALLESTER,* M. BALLESTER, AND J. P. BELAICH 784–788

GR-20263: a New Aminothiazolyl Cephalosporin with High Activity Against *Pseudomonas* and *Enterobacteriaceae*. LUDO VERBIST* AND JAN VERHAEGEN 807–812

Rapid Determination of Minimum Inhibitory Concentrations of Antimicrobial Agents by Regression Analysis of Light Scattering Data. JAMES E. MCKIE, JOHN SEO,* AND JAMES N. ARVESEN 813–823

Rapid Determination of Minimum Inhibitory Concentrations of Antimicrobial Agents by the Autobac Method: a Collaborative Study. F. D. SCHOENKNECHT,* J. A. WASHINGTON II, T. L. GAVAN, AND C. THORNSBERRY 824–833

Comparison of Moxalactam (LY127935) and Cefotaxime Against Anaerobic Bacteria. J. H. JORGENSEN,* S. A. CRAWFORD, AND G. A. ALEXANDER 901–904

Activity of Ten Cephalosporins on Biomass of Methicillin-Susceptible and -Resistant *Staphylococcus aureus*. E. Yourassowsky,* M. P. Van der Linden, M. J. Lismont, and F. Crokaert 856–860

Plaque Inhibition Assay for Drug Susceptibility Testing of Influenza Viruses. Frederick G. Hayden,* Kim M. Cote, and R. Gordon Douglas, Jr. 865–870

In Vitro Activities of Miconazole, Miconazole Nitrate, and Ketoconazole Alone and Combined with Rifampin Against *Candida* spp. and *Torulopsis glabrata* Recovered from Cancer Patients. M. R. Moody,* V. M. Young, M. J. Morris, and S. C. Schimpff 871–875

Comparison of In Vitro Activity of GR 20263, a Novel Cephalosporin Derivative, with Activities of Other Beta-Lactam Compounds. R. Wise,* J. M. Andrews, and K. A. Bedford 884–889

Pharmacology and Therapeutics

Evaluation of an Enzyme Immunoassay for Serum Gentamicin. Thomas D. O'Leary, Rodney M. Ratcliff,* and Terence D. Geary .....

Concentrations of Various Antibiotics in Serum and Fluids Accumulated in Diffusion Chambers Implanted in Various Sites in Rabbits. A. Georgopoulos* and E. Schütze 779–783

New Schedule for Tobramycin Administration. Ronald D. Lawson, Gerald P. Bodey,* Theresa Pan, and Terry L. Smith 834–837

Biliary Excretion of Cephalosporins in Rats: Influence of Molecular Weight. Walter E. Wright* and Verle D. Line 842–846

Effect of Orally Administered Probenecid on the Pharmacokinetics of Cefoxitin. Peter H. Vlasses, Anne M. Holbrook, John J. Schrogie, J. Douglas Rogers, Roger K. Ferguson,* and William B. Abrams 847–855

GR 20263, a New Broad-Spectrum Cephalosporin with Anti-Pseudomonal Activity. Cynthia H. O'Callaghan,* P. Acred, P. B. Harper, D. M. Ryan, Susan M. Kirby, and S. M. Harding 876–883

Volume 17 Contents for June **Number 6**

Biosynthesis; Chemistry; Mechanisms of Action and Resistance

In Vitro and In Vivo Effects of the Antimycotic Drug Ketoconazole on Sterol Synthesis. Hugo Van den Bossche,* Gustaaf Willemsens, Willy Cools, Frans Cornelissen, William F. Lauwers, and Jan M. van Cutsem 922–928

Principal β-Lactamases Responsible for Resistance to β-Lactam Antibiotics in Urinary Tract Infections. Iain N. Simpson,* Paul B. Harper, and Cynthia H. O'Callaghan 929–936

Defective Killing of Enterococci: a Common Property of Antimicrobial Agents Acting on the Cell Wall. Donald J. Krogstad* and Arlene R. Parquette 965–968

Type II Interferon Induction and Passive Transfer Depress the Murine Cytochrome P-450 Drug Metabolism System. Gerald Sonnenfeld,* Cindy L. Harned, Suthep Thaniyavarn, Thomas Huff, Adrian D. Mandel, and Donald E. Nerland 969–972

Some Chemical and Physical Characteristics of Pantomycin, an Antibiotic Isolated from *Streptomyces hygroscopicus*. S. GURUSIDDAIAH* AND S. O. GRAHAM 980–987

Interferon Induction by and Toxicity of Polyriboinosinic Acid [Poly(rI)]·Polyribocytidylic Acid [Poly(rC)], Mismatched Analog Poly(rI)·Poly[r(C_{12}Uracil)*n*], and Poly(rI)·Poly(rC) L-Lysine Complexed with Carboxymethylcellulose. DALE A. STRINGFELLOW* AND SHELDON D. WEED 988–992

Hydrolysis of Cefotaxime by a Beta-Lactamase from *Bacteroides fragilis*. J. C. PECHÈRE,* R. GUAY, J. DUBOIS, AND R. LETARTE 1001–1003

Antiviral Activity of Tunicamycin on Herpes Simplex Virus. EHUD KATZ,* EVA MARGALITH, AND DAN DUKSIN 1014–1022

Antiherpesviral Activity and Inhibitory Action on Cell Growth of 5-Alkenyl Derivatives of 1-β-D-Arabinofuranosyluracil. HARUHIKO MACHIDA,* AKIRA KUNINAKA, HIROSHI YOSHINO, KAZUYOSHI IKEDA, AND YOSHIHISA MIZUNO 1030–1031

Inhibition of Herpes Simplex Virus Multiplication by the Pokeweed Antiviral Protein. GARY M. ARON* AND JAMES D. IRVIN 1032–1033

Mechanism of Virucidal Activity of Retinoids: Protein Removal from Bacteriophage ø6 Envelope. ALBERT REINHARDT, DAVID AUPERIN, AND JEFFREY SANDS* 1034–1037

Physiological Effects and Microbial Susceptibility

Combined Antibacterial Activity of Amoxicillin with Clavulanic Acid Against Ampicillin-Resistant Strains. M. MATSUURA,* H. NAKAZAWA, T. HASHIMOTO, AND S. MITSUHASHI 908–911

Antibacterial Activities of a New Stabilized Thienamycin, *N*-Formimidoyl Thienamycin, in Comparison with Other Antibiotics. TADATAKA KESADO,* TERUTAKA HASHIZUME, AND YOSHINARI ASAHI 912–917

Factors Affecting Gentamicin Assay. LENNART NILSSON 918–921

In Vitro Activities of Moxalactam and Cefotaxime Against Aerobic Gram-Negative Bacilli. J. H. JORGENSEN,* S. A. CRAWFORD, AND G. A. ALEXANDER 937–942

Susceptibility of *Bacterium actinomycetem comitans* to 45 Antibiotics. ULRICH HÖFFLER,* WALTER NIEDERAU, AND GERHARD PULVERER 943–946

In Vitro Activity of Mecillinam Against Anerobic Bacteria. GREGORY E. STEINKRAUS* AND LAURENCE R. MCCARTHY 954–956

Susceptibilities of Anaerobic Bacteria to Cefoperazone and Other Antibiotics. DONALD KAYE,* WILLIAM KOBASA, AND KAREN KAYE 957–960

MK0787 (*N*-Formimidoyl Thienamycin): Evaluation of In Vitro and In Vivo Activities. HELMUT KROPP,* JON G. SUNDELOF, JEAN S. KAHAN, FREDERICK M. KAHAN, AND JEROME BIRNBAUM 993–1000

Pharmacology and Therapeutics

Effect of Pancreatitis on Ampicillin Excretion in Pancreatic Fluids of Dogs. ETHAN RUBINSTEIN,* JACOB HASPEL, EHUD KLEIN, GUR BEN-ARI, RENATA SCHWARZKOPF AND AMNON TADMOR 905–907

Effect of Acyclovir on Proliferation of Human Fibroblasts and Peripheral Blood Mononuclear Cells. MYRON J. LEVIN,* PATRICIA L. LEARY, AND ROBERT D. ARBEIT 947–953

Sulfamethoxazole-Trimethoprim Versus Ampicillin in Treatment of Acute Invasive Diarrhea in Adults. F. A. BARADA, JR., AND R. L. GUERRANT* 961–964

Pharmacokinetics of Alafosfalin, Alone and in Combination With Cephalexin, in Humans. JOHN G. ALLEN* AND LORNA J. LEES 973–979

Therapy of Obstetrical Infections with Moxalactam. RONALD S. GIBBS,* JORGE D. BLANCO, YOLANDA S. CASTANEDA, AND PATRICIA J. ST. CLAIR 1004–1007

Mezlocillin for Treatment of Infections in Cancer Patients. BRIAN F. ISSELL AND GERALD P. BODEY* 1008–1013

Failure of Single Doses of Cefazolin and Cefamandole to Penetrate Experimental Chronic *Escherichia coli* Abdominal Abscesses. DALE N. GERDING,* ALAN J. KOZAK, LANCE R. PETERSON, AND WENDELL H. HALL 1023–1029

INDEX TO DATE OF ISSUE

Month	Date of Issue	Pages
January	29 January 1980	1–102
February	19 March 1980	103–291
March	21 April 1980	293–517
April	29 April 1980	519–761
May	28 May 1980	763–904
June	9 July 1980	905–1037

AUTHOR INDEX

VOLUME 18

Abe, Hiromu, 980
Adachi, Kimiko, 513
Agee, C. Coe, 243
Agyare, Emmanuel O., 832
Ahmad, M. H., 798
Akiyama, Shin-ichi, 226
Alestig, Kjell, 349
Amatnieks, Yuri E., 101
Andrews, Jenny M., 844
Angehrn, Peter, 913
Anné, Jozef, 231
Apollo, Elaine, 784
Arai, Susumu, 1
Arango, María D., 190
Arnaud, J. P., 69
Arnett, Gussie, 598
Aronoff, George R., 212
Atherton, Frank R., 897
Atkinson, Barbara, 807

Badal, R. E., 338
Badal, Robert E., 773
Badaracco, Gianfranco, 50
Baker, C. N., 338
Baker, Carolyn N., 773
Baker, John S., 872
Baker, S., 369
Baldwin, Jack E., 465
Balt, Sijbe, 249
Barriere, Steven L., 952
Barry, A. L., 338, 716
Barry, Arthur L., 88, 487, 616, 773
Barton, Nancy H., 709
Behar, Caren F., 722
Bekesi, J. George, 622
Bekki, Eiichi, 980
Bennett, Peter M., 200
Bennett, William M., 346
Bergstrom, Donald E., 957
Biron, Karen K., 443
Block, Colin S., 493
Blomster, Ralph N., 171
Böck, August, 798
Bodey, Gerald P., 574, 939
Bollinger, Mitzi, 474
Bolton, L., 137
Bolton, W. Kline, 933
Bongaerts, Ger P. A., 680
Bowie, W. R., 978
Brajtburg, Janina, 586, 593
Brogard, J. M., 59
Brook, Itzhak, 164
Broughall, John M., 844
Bruggeman-Ogle, Kristiane M., 680
Brunken, Jan M., 474
Bryan, L. E., 390
Buchanan, Robert A., 709
Burd, John F., 264
Burdett, Vickers, 753
Burgess, Keith R., 829
Butzler, J. P., 118
Bywater, Martin J., 844

Calhoun, Leslie, 164
Came, Paul E., 738
Caplan, Ellis S., 448
Carp, R. I., 276
Carrizosa, J., 564
Casero, Robert A., Jr., 317
Cassel, Robert, 493
Chai, Toby C., 638
Chai, Tuu-jyi, 638
Chapman, Stanley W., 699
Chen, Ming S., 433
Cheng, Yung-chi, 957
Cherne, John E., 210
Cherubin, Charles E., 893
Childs, George E., 317
Chrystal, Ewan J. T., 568
Clavel, Sabine, 357
Clement, Françoise, 357
Cobbs, C. Glenn, 709
Cohen, Seymour S., 598
Cohn, John R., 872
Coignau, H., 118
Comber, K. R., 182
Contacos, Peter G., 289
Conte, John E., Jr., 952
Coppens, L., 437
Corrado, Michael L., 893
Courtney, Mary-Anne, 926
Coyle, Marie, 814
Crowlesmith, Ian, 667, 675
Crum, John W., 360
Crutzen, Ans Q. H., 521

Dabernat, Henry J., 841
Daniel, Muthiah D., 622
Dann, Otto, 231
David, Hugo L., 357
Davis, Henry T., 699
de Bolster, Martinus W. G., 249
De Clercq, Erik, 231
De Grandis, S., 948
Delmas, Catherine F., 841
Demain, Arnold L., 465
Desjardins, Robert E., 317
Dessens-Kroon, M., 789
Dick, J. D., 158
Dickson, Edward T., 27
Dierickx, R., 118
Diethelm, Arnold G., 709
Dobek, Arthur S., 27
Döbeli, H., 111
Dobson, Richard A., 738
Dornbusch, Kathrine, 220
Dorner, M., 69
Dougherty, Thomas J., 730
Douglas, R. Gordon, Jr., 538
Dowell, V. R., Jr., 13
Duangmani, Chiraphun, 360

Eda, Yasuko, 37
Edberg, Stephen C., 722
Edelstein, Paul H., 403
Elberg, Svetlana, 586, 593
Elion, Gertrude B., 443, 741
Elm, Joe L., Jr., 125
Engelhardt, J. A., 243
Evans, Richard T., 9
Eyssen, Hendrik, 231

Falk, Lawrence A., 622
Fass, Robert J., 483, 906
Fayolle, Françoise, 504
Felsenfeld, Ambhan D., 142
Field, A. Kirk, 929
Finegold, Carolynn, 586
Fique, Dorothy V., 171
Fleischaker, Robert J., 130
Fleming, P. C., 948
Foleno, B., 137
Förster, Dieter, 81
Fortner, Clarence L., 299
Frère, Jean-Marie, 508
Fu, Kwung P., 311, 582
Fuchs, Peter C., 88
Furman, Phillip A., 741

Gabridge, M. G., 243
Gambertoglio, John G., 952
Garcia, Juan M., 215
Gatmaitan, Bienvenido G., 409
Gavan, Thomas L., 88
Genco, Robert J., 9
Georgopapadakou, Nafsika H., 148, 834
Geraci, Joseph E., 944
Gerlach, E. H., 716
Gerlach, E. Hugh, 88, 616
Gerone, Peter J., 142
Ghuysen, Jean-Marie, 508
Giard, Donald J., 130
Gibson, Susan, 142
Gilbert, David N., 346
Gillett, A. P., 240
Ginelli, Enrico, 50
Girolami, Roland L., 766
Gitelman, J., 962
Goldman, Peter, 568

Goldstein, Alma, 761
Goldstein, Ellie J. C., 832
Gombert, Myles E., 832
Gorbach, Sherwood L., 167, 642
Gordon, Leon L., 176
Gordts, B., 118
Goto, Mitsuyoshi, 372
Grill, Susan, 957
Grinsted, John, 200
Groman, Neal, 814
Grossberg, Sidney E., 20

Hakenbeck, Regine, 629
Hall, Michael J., 897
Halstead, Scott B., 125
Haltiner, Rita C., 365
Hamilton, Bruce K., 454
Hamparian, Vincent V., 269
Harawawa, Ryô, 58
Hardisson, Carlos, 215
Hardy, D. J., 544
Harris, Patricia C., 922
Harvey, Robert J., 323
Hashimoto, Ikuo, 980
Hassall, Cedric H., 897
Hatheway, Charles L., 13
Hayden, Frederick G., 538
Herbert, Pamela, 355
Hewitt, William L., 645
Hilleman, Maurice R., 929
Hindler, Janet A., 645
Hinkle, Anne M., 574
Hirasawa, Sadako, 980
Hirose, Toshiharu, 377
Hirtz, Jean L., 656
Holland, James S., 622
Holley, H. Preston, 448
Holmes, Simon W., 897
Holt, Alan, 844
Hopke, Charles J., 929
Horadam, Victor W., 559
Hottendorf, G. H., 176, 746
Houghton, Donald C., 346
Howe, T. G. B., 667, 675
Hughes, John H., 269
Humbert, Guy, 656
Hurley, David J., 969

Inbar, M., 962
Inoue, M., 837
Inoue, Matsuhisa, 77, 382, 687, 853
Irie, Kenji, 37
Isaacs, Linda L., 983
Ishizaki, Takashi, 372
Iwahi, Tomoyuki, 257
Iwai, Yuzuru, 691
Izawa, Akio, 37, 41, 45

Jacks, Thomas M., 397
Jacobus, Nilda V., 642
Jertborn, Marianne, 349
Johnson, Paulette, 761
Jones, Benjamin V., 416
Jones, R. N., 338, 716
Jones, Ronald N., 88, 487, 616, 773
Jørgensen, Sigrid Tue, 200
Judith, Frederick R., 397
Jungkind, Donald L., 872

Kabat, William J., 122
Kailasam, S., 661
Kampf, Dieter, 81
Kaneko, Masae, 226
Karmali, M. A., 948
Kawahara, Kazuo, 45
Kaye, D., 564
Kim, H., 780
Kim, K. S., 276
King, Anna, 292
King, Norval W., 622
Kinkel, Arlyn W., 709
Kisaki, Yoko, 37
Kitao, Chiaki, 691
Klastersky, J., 437
Klayman, Daniel L., 27, 317
Klein, Daniel, 508
Kleit, Stuart A., 212
Kobasa, W. D., 564
Kobayashi, George S., 586, 593
Koch, Arthur L., 323
Koch, Ronald L., 568
Koff, Wayne C., 125
Kohn, A., 962
Koller, Antje E., 730
Komatsu, Toshiaki, 37, 41, 45
Komiyama, Sohtaro, 226
Kondo, Takao, 513
Koornhof, Hendrik J., 493
Kopferschmitt, J., 69
Krontz, Daniel P., 882
Kundsin, Ruth B., 738
Kurashige, S., 105
Kuroda, Kyoichi, 386
Kurtz, Terrance O., 645
Kuwano, Michihiko, 226

Lambert, Robert W., 897
Landesman, Sheldon H., 893
Lareng, Marie B., 841
Lavillaureix, J., 69
Lecaillon, Jean B., 656
Lee, Francis H., 746
Legeai, R. J., 544
Lerman, Stephen J., 474
Lerner, A. Martin, 409
Levy, Hilton B., 409
Lietman, Paul S., 534
Lin, C., 780
Lin, Emil T., 952
Lipsky, James J., 534
Liu, Fung Y., 148, 834
Livingston, R., 240, 369
Llaneza, Juan, 215
Lloyd, William J., 897
Lobbins, Phyllis M., 9
Logan, Margaret N., 844
Lorian, Victor, 807
Lubbers, Carol M., 741
Luft, Friedrich C., 983
Lysko, Paul G., 281, 416

Mandel, Laura J., 722
Marcus, Edwin L., 212
Markowitz, Sheldon M., 651
Marks, Melvin I., 579
Marlin, Graham E., 829
Martin, Jerry R., 761
Martin, William J., 645
Masuyoshi, Shinji, 1
Matsubara, Nobuyuki, 195
Matsuhashi, Michio, 195
Matsumoto, Joseph Y., 944
Matsuura, Masayuki, 687
Mayhall, C. Glen, 784
McCracken, George H., Jr., 476
McCroskey, Loretta M., 13
McDonough, P., 480
McGuffin, Robert W., 471
McGuire, Jeffrey C., 454
McLafferty, Martha A., 568
Means, B., 137
Medoff, Gerald, 586, 593
Mehl, J. Kurt, 269
Meisel, Steven, 206
Melo, Julio, 926
Menday, A. P., 437
Mendez, Francisco J., 215
Mendoza, Carmen, 215
Merz, W. G., 158
Meunier-Carpentier, F., 437
Meyer, Richard D., 403
Meyers, Joel D., 471
Middelbeek, Evert J., 521
Migneault, Paula C., 365
Mikami, Jiroh, 980
Miller, Brinton M., 397
Miller, James R., 926
Miller, Michael H., 722
Minami, Shinzaburo, 77, 195, 382, 853
Mitsuhashi, S., 105, 837
Mitsuhashi, Susumu, 1, 77, 195, 382, 687, 853
Mitsuoka, Tomotari, 58
Miyamoto, Masaki, 1
Moniz-Pereira, José, 357
Montgomery, Carol L., 559
Moody, Marcia R., 299
Morse, Stephen A., 281, 416
Mourad, Aly, 696
Murakawa, Takeo, 377
Murillo, Jorge, 448
Mutimer, Malcolm D., 976

Nair, N. G. K., 661
Nakagome, Takenari, 37
Nakamura, Takashi, 980
Nakashita, Einosuke, 386
Nakazawa, H., 837

Nakazawa, Hisashi, 687
Narayana, A. S. L., 661
Nauta, Wijbe T., 249
Nelson, John D., 476
Nelson, Robert L., 212
Neu, Harold C., 311, 582
Newman, Kathryn A., 299
Nishi, Takeshi, 551
Nishida, Minoru, 377
Nord, Carl Erik, 220
North, Thomas W., 598
Nüesch, J., 111

O'Callaghan, R. J., 544
O'Connor, John R., 738
Oden, E., 780
Ohkawa, Mitsuo, 386
Oill, Phyllis A., 355
Oliva, Brunello, 200
Olsson-Liljequist, Barbro, 220
Ōmura, Satoshi, 691
Orito, Matsuo, 386
Ortiz, José M., 215
Overby, Terry L., 933
Owens, Lynn M., 610

Packer, R. R., 338
Packer, Richard R., 773
Panwalker, Anand P., 877
Parker, Richard A., 346
Parks, L. W., 822
Pass, Robert F., 709
Pearson, Richard D., 699
Pelzer, Helmut, 887
Penner, J. L., 868
Percheson, P. B., 390
Pesanti, Edward L., 208
Peterson, Lance R., 210
Petrucelli, S., 137
Phillips, Ian, 292
Pieper, John A., 604
Piepersberg, Wolfgang, 863
Pijper, Pieter J., 249
Plevani, Paolo, 50
Pohlod, Donald J., 353
Porembski, Priscilla E., 877
Porter, George A., 346
Poulin, Sharon A., 738
Preston, M. A., 868
Privitera, Gaetano, 504
Probst, Peter J., 913
Prusoff, William H., 433
Pupkoff, Robert, 206

Quinn, Edward L., 353

Raff, Martin J., 926
Raghupati Sarma, G., 661
Ralph, Edward D., 101
Rankin, Laura I., 983
Rechenmacher, Angelika, 798
Reeves, David S., 844
Reiner, Roland, 913
Restrepo M. Angela, 190
Reuter, Wolfgang, 887
Ringrose, Peter S., 897
Roberts, Marilyn C., 610
Robertson, Richard G., 365
Robinson, Roy G., 493
Rodriguez, R. J., 822
Rogers, Henry J., 63
Rosenblum, Eugene D., 424
Ruebush, Trenton K., II, 289
Ruth, Jerry, 957

Sakamoto, Hiroshi, 377
Sande, Merle A., 933
Sanders, William J., 531
Sapienza, V. J., 276
Saral, R., 158
Saravolatz, Louis D., 353
Sasahara, Kunihiro, 386
Sato, K., 837
Saunders, Jean, 493
Sawada, Yasuo, 980
Sawada, Yosuke, 465
Sawaki, Masaru, 386
Scattergood, Edgar M., 929
Schabel, Frank M., Jr., 598
Schachter, Julius, 696
Schentag, Jerome J., 604
Schiller, John, 814
Schimpff, Stephen C., 299
Schleim, Klaus-Dieter, 397
Schoeller, Jean P., 656
Schoenherr, Christine K., 20
Schuessler, D., 780
Schurig, Randolf, 81
Scovill, John P., 27, 317
Sealey, Lynn B., 922
Sebald, Madeleine, 504
Seddon, M., 240
Shannon, Kevin, 292
Shannon, William M., 598
Sheld, W. Michael, 933
Shelton, Sharon, 476
Shiau, George T., 433
Shibata, Sharon A., 355
Shimamura, Masayoshi, 386
Shin, S., 480
Shiota, Faith M., 471
Shono, Fumiaki, 45
Sibilla, Denise J., 651
Simon, Gary L., 167
Simons, Ruth, 538
Singh, Pushpa D., 465
Slots, Jørgen, 9
Smilack, Jerry D., 559
Smit, Hendrik, 249
Smith, Arnold L., 610
Smith, Thomas F., 738
Smyth, Robert D., 746
Snydman, David R., 167
Soike, Kenneth F., 142
Solomon, Nadine A., 465
Somerville, Margaret M., 353
Sommers, Herbert M., 88
Sora, Silvio, 50
Speedie, Marilyn K., 171
Spyker, Daniel A., 933
Stamm, John M., 766
Standiford, Harold C., 448
St. Clair, Marty H., 741
Steck, Edgar A., 289
Steigbigel, Neal H., 722
Steigbigel, Roy T., 699
Stewart, George C., 424
Stöcklein, Walter, 863
Stouthamer, Adrian H., 249
Strausbaugh, Larry J., 882
Streips, Uldis N., 926
Stroshane, Ronald M., 454
Sugata, Toshiaki, 386
Sugg, Nancy, 696
Sugimoto, Yoshikazu, 527
Sugiyama, Masatoshi, 372
Summersgill, James, 926
Sutherland, R., 182
Suthisomboon, Kalaya, 360
Suzuki, Kunio, 58
Svaan, John, 206
Svedhem, Åke, 349
Sweet, Richard L., 696
Swenson, Christina D., 610
Swenson, Jana M., 13
Symchowicz, S., 780
Synge, Charlotte, 63
Szwed, James J., 212

Tabuki, Toshiko, 226
Tadanier, Jack, 761
Tainturier, Daniel J., 841
Takaoka, Masayoshi, 195
Tally, Francis P., 167, 642
Tamulevich, Ruth, 622
Tanaka, Haruo, 691
Tanaka, Yoshitake, 691
Tanayama, Shigeharu, 513
Tarpay, Martha M., 579
Tatem, Beverly A., 448
Taylor, Diane E., 480
Taylor, Jerry L., 20
Then, Rudolf L., 913
Thomas, Monica C., 454
Thompson, Philip J., 829
Thompson, Stephan G., 264
Thornsberry, C., 338, 716
Thornsberry, Clyde, 13, 88, 487, 616, 773
Tight, Robert R., 307
Timoney, J. F., 480
Toda, M., 837
Tomasz, Alexander, 629, 730
Toyoshima, Shigeshi, 527
Trager, Gary M., 877
Tramont, Edmund C., 27
Tripathy, S. P., 661
Tsuchiya, Kanji, 257, 551
Tucker, Bruce C., 709
Tytell, Alfred A., 929

Umeda, Isao, 45

van der Goot, Henderikus, 249
van Embden, J. D. A., 789
Van Harken, Donald R., 746
Vanhoof, R., 118
van Klingeren, B., 789
van Wijngaarden, L. J., 789
Vasiljev, Michael, 746
Verheul, Henk, 249
Vibulyasekha, Somnuk, 360
Vidal, Ronald A., 604
Vis, Ronald D., 249
Vischer, Wolfgang, 656
Vogels, Godfried D., 521

Wade, James C., 299
Waisbren, Burton A., 969
Waisbren, Steven J., 969
Warren, Christine, 292
Washington, John A., II, 944
Watanabe, Yasuo, 980
Weaver, Susanne S., 939
Weihermüller, Klaus, 81
Welch, David F., 579
Werner, Rolf G., 858
Werringloer, Jurgen, 559
Whelchel, John D., 709
White, A. R., 182
White, Richard J., 454
Whitley, Richard J., 709
Wiernik, Peter H., 299
Williamson, Russell, 629
Wilson, Walter R., 944
Winston, Drew J., 645
Wise, R., 240, 369
Wise, Richard, 844
Witiak, Donald T., 269
Wolinsky, Emanuel, 531
Woods, Vivienne E., 63
Woolcock, John B., 976
Wright, Alan J., 944

Yasuda, K., 105
Yocum, Paula, 164
Yogev, Ram, 122
Yoshida, Kiyoshi, 513
Yoshikawa, Thomas T., 355
Yoshitake, Akira, 41, 45
Yotsuji, Akira, 382
Young, Lowell S., 645
Young, Viola Mae, 299
Yum, Moo N., 983

Zimmermann, Willy, 94

SUBJECT INDEX

VOLUME 18

Acycloguanosine
  herpesviruses, 622
Acyclovir
  granulocyte progenitor cells, 471
  varicella-zoster virus, 443
Acyclovir triphosphate
  inhibition of DNA polymerases, 741
Adenosine triphosphatase
  inhibition by neomycin, 532
Aeromonas hydrophila
  cefoperazone, 483
Alafosfalin
  related phosphonopeptide antibacterial agents, 897
D-Alanyl-D-alanine
  analogs inhibiting *E. coli* murein synthesis, 887
Amikacin
  disk susceptibility test interpretation, 616
  nephrotoxicity in rat model, 983
δ-(L-α-Aminoadipyl)-L-cysteinyl-D-valine
  cyclization to isopenicillin N, 465
5′-Amino-5′-deoxythymidine
  diphosphate derivative, 433
  herpes simplex virus inhibitor, 433
  synthesis, 433
Aminoglycosides
  carbenicillin interactions, in vitro and in vivo, 604
  combination with newer cephalosporins, 651
  gram-negative bacilli, 645
  O-demethylfortimicin A, compared, 773
  uptake and ribosomal resistance mutations, 798
Amphotericin B
  antifungal, K^+, Na^+, and Mg^{2+} influence, 593
  ion influence on antifungal activity, 593
Ampicillin
  resistant *H. influenzae* surveillance, 474
  S. aureus susceptibility by Autobac I, 922
Animal model
  carbenicillin-aminoglycoside interactions, 604
Antagonism
  erythromycin, 872
Antifungal agents
  15-azasterol, produced by *G. flavo-brunneum*, 822
Antimicrobial susceptibility
  three *Providencia* species compared, 868
Antiviral agents
  enhanced activity in combination, 536
  influenza viruses, 536
9-β-D-Arabinofuranosyladenine
  enhancement by *erythro*-9-(2-hydroxy-3-nonyl)-adenine, 598
  systemic herpesvirus infections in mice, 598
Autobac I
  S. aureus susceptibility to penicillin and ampicillin, 922
15-Azasterol
  production in *G. flavo-brunneum*, 822

Bactericidal efficacy
  in vitro kinetic model, 377
Bacteroides fragilis
  tetracycline transport, 502
Bile
  cefoperazone concentrations, 980

Campylobacter fetus subsp. *fetus* (*intestinalis*)
  cephalosporins susceptibility, 948
  susceptibility different from *C. jejuni*, 948
Campylobacter jejuni
  cephalosporins susceptibility, 948
  susceptibility different from *C. fetus* subsp. *fetus*, 948
Cantharides-induced blisters
  pharmacokinetics
    cefotaxime, 369
    moxalactam, 369
Carbenicillin
  cefazolin-mecillinam combination, 437
  interactions with aminoglycosides, in vitro and in vivo, 604
  septicemia caused by gram-negative organisms, 437
Cefazolin
  K. pneumoniae DT-S in mice, 549
  plus mecillinam-carbenicillin, 437
  S. aureus endocarditis in rabbits, 562
Cefmetazole
  impaired renal function, 386
  pharmacokinetics in normal humans, 386
Cefoperazone
  A. hydrophila, 483
  concentrations in bile and gall bladder wall, 980
  gram-negative bacilli, 645
  inoculum effect on *P. aeruginosa* susceptibility, 893
  nonfermenters, 483
Ceforanide
  S. aureus endocarditis in rabbits, 562
Cefotaxime
  gram-negative bacilli, 645
  gram-negative bacilli, pediatrics, 476
  inoculum effect on *P. aeruginosa* susceptibility, 893
  vs. moxalactam
    pharmacokinetics, 369
    tissue levels, 369
Cefotiam
  K. pneumoniae DT-S in mice, 549
Cefroxadin (CGP 9000)
  pharmacokinetics, human, 656
Cephalexin
  pharmacokinetics, human, 656
Cephalosporin β-lactamase (cephalosporinase)
  from *E. cloacae*, 853
Cephalosporins
  C. fetus subsp. *fetus* versus *C. jejuni* susceptibility, 948
  newer, *S. marcescens* susceptibility, 651
Cephamycin C
  enterotoxigenic colibacillosis, 397

Cerebrospinal fluid
vancomycin penetration in rabbits, 882
Cerumen
bactericidal activity, 638
Chlamydia trachomatis
erythromycin, relative resistance, 696
rosaramicin activity in vitro, 978
rosoxacin, 738
susceptibility in tissue culture system, 696
Chloramphenicol
resistant *H. influenzae*, characterization, 610
CI-867
new semisynthetic penicillin, 939
Clavulanic acid
synergy with piperacillin, 582
N^{α}-Cocoyl-L-arginine ethyl ester
hepatitis B surface antigen inactivation, 525
Compound A49759
O-demethylfortimicin A, 766, 773
Contagious equine metritis
H. equigenitalis susceptibility, 841
Corynebacterium diphtheriae
erythromycin resistance plasmids, 814
Corynebacterium equi
susceptibility, 976
Cycloheximide
ribosomal binding in *S. cerevisiae*, 863

Daunorubicin glycosides
biosynthesis, 454
ε-rhodomycinone, 454
O-Demethylfortimicin A
comparative antimicrobial activity, 766
compared with aminoglycosides, 773
3-*O*-Demethylfortimicins
synthesis, 761
Deoxyribonucleic acid polymerases
inhibition by acyclovir triphosphate, 741
Dibekacin
nephrotoxicity in rat model, 983
pharmacokinetics, human, 372
Diffusion susceptibility test
interpretive criteria, 487
netilmicin, 30-μg disks, 487
Disk susceptibility tests
amikacin, interpretive standards, 616
moxalactam, interpretive standards, 716
Sch 21420, interpretive standards, 616

Eikenella corrodens
susceptibility to newer β-lactams, 832
Endocarditis, enterococcal
prophylaxis, 448
Enterobacter cloacae
cephalosporinase, 853
β-Lactamase induction by antibiotics, 382
Enterococci
penicillin/aminoglycoside synergy, 944
thymine-thymidine requiring, 365
Enterotoxigenic colibacillosis
cephamycin C
calves, 397
piglets, 397
Erythro-9-(2-hydroxy-3-nonyl)adenine
combination with araA, 598
systemic herpesvirus infections in mice, 598
Erythromycin
antagonism to other drugs, 872
C. trachomatis resistance, 696
resistance plasmids
C. diphtheriae, 814
diphtheroids, 814
Erythromycin ethyl succinate
effect of food on absorption, 829
Escherichia coli
murein synthesis inhibition, 887

Fatty acids
inactivation of enveloped viruses, 962
Food
effect on erythromycin ethyl succinate absorption, 829
N-Formimidoyl thienamycin
activity vs. β-lactamase producers, 837
crystalline derivative of thienamycin, 557
effect of β-lactamases, 837
inoculum effect on *P. aeruginosa* susceptibility, 893
in vitro activity, 557, :642
Fortimicin A
O-demethylfortimicin A, comparative activity, 766
Fortimicin B
synthesis of 3-*O*-demethylfortimicins, 761

Gall bladder
cefoperazone concentrations in wall, 980
Gentamicin
nephrotoxicity in rat model, 983
prophylaxis against enterococcal enterocarditis, 448
synergy with penicillin against enterococci, 944
uptake by *S. aureus* mutants, 722
Geotrichum flavo-brunneum
antifungal homoazasterol production, 822
growth, 822
Gram-negative bacilli
cefotaxime, 476
cephalosporins, 476
moxalactam, 476
moxalactam, cefotaxime, cefoperazone, piperacillin, aminoglycosides, 645
pediatric isolates, drug susceptibility, 476
Ro 13-9904, 476
Gram-positive bacteria
indolmycin uptake, 858
Granulocyte progenitor cells
acyclovir nontoxicity, 471
Group B streptococci
tetracycline-resistant R plasmids, 753

Haemophilus equigenitalis
susceptibility, 841
Haemophilus influenzae
ampicillin resistance surveillance, 474
chloramphenicol resistant, 610
plasmid characterization of resistant strains, 610
Hepatitis B surface antigen
effect of N^{α}-cocoyl-L-arginine ethyl ester, 525
Herpes simplex virus

E-5-propenyl-2′-deoxyuridine activity, 957
Herpesvirus
adenine nucleoside analogs in combination, 598
comparative study, interferon and 3 agents, 622
High-pressure liquid chromatography
rosaramicin determination in human serum, 780
Homoazasterol
production in *G. flavo-brunneum*, 822
Human albumin
medium for interferon-producing Namalva cells, 929
Human erythrocytes
polyene antibiotics, large and small, effects, 586
Human polymorphonuclear leukocytes
killing of oxacillin-exposed *S. aureus*, 807

Indolmycin
uptake in gram-positive bacteria, 858
Influenza viruses
drug combinations, enhanced activity, 536
Interferon
Namalva cells in medium with human albumin, 929
Interferon, human lymphoblastic
herpesviruses, 622
Isoniazid
effect of rifampin and prednisolone on metabolism, 661
Isopenicillin N
from δ-(L-α-aminoadipyl)-L-cysteinyl-D-valine, 465

Klebsiella pneumoniae
broadening aminoglycoside resistance 542
cefazolin, 549
cefotiam, 549
kanamycin resistance, 542
mouse experimental pneumonia, 549
R-factor determining multiple resistance, 926
Klebsiella spp.
bactericidal kinetics, 877
inactivation of β-lactam drugs, 877
susceptibility, 877

β-Lactam antibiotics
binding to penicillin-binding proteins, 834
enzymatic method for quantitation, 506
N-formimidoyl thienamycin in vitro, 557, 642
inactivtion by *Klebsiella* spp., 877
β-lactamase induction in *E. cloacae*, 382
mecillinam alone and in combination, 906
newer, *E. corrodens* susceptibility, 832
S. pneumoniae penicillin-binding proteins, 629
β-Lactamase
deficient R1 and RP1 plasmid mutants, 667
N-formimidoyl thienamycin
activity against producer, 837
effect, 837
from *P. rettgeri*, purification and properties, 687
induction in *E. cloacae*, 382
mecillinam susceptibility of enterobacteria, 680
R plasmid mutants, pencillin resistance, 675
β-Lactamase inhibitors
synergy with piperacillin, 582
Legionella pneumophila
susceptibility to 20 drugs, 403

Leucomycin
effect of magnesium phosphate on production, 691
S. kitasatoensis, 691

Magnesium ions
influence on antifungal amphotericin B, 593
Magnesium phosphate
leucomycin production by *S. kitasatoensis*, 691
Mechanism of action
pyocin vs. *N. gonorrhoeae*, 416
Mecillinam
activity alone and in combination, 906
added to carbenicillin-cefazolin, 437
enterobacterial susceptibility, 680
β-lactamase and salt effects, 680
pharmacokinetics in healthy volunteers, 952
Methicillin
resistance transduction to *S. aureus*, 424
S. aureus endocarditis in rabbits, 562
Metronidazole
metabolism and bactericidal activity, 566
Micro-broth dilution
S. pneumoniae susceptibility testing, 579
Minimal bactericidal antibiotic concentrations
S. aureus, reliable determination, 699
Minimal lethal antibiotic concentrations
S. aureus, reliable determination, 699
Minimum inhibitory concentration testing
sensititre microtitration trays, 844
Moxalactam
disk susceptibility test interpretive standards, 716
gram-negative bacilli, 645
gram-negative bacilli, pediatrics, 476
inoculum effect on *P. aeruginosa* susceptibility, 893
in patients with renal dysfunction, 933
pharmacokinetics, 369
tissue levels, 369
Mueller-Hinton agar
thymidine-dependent enterococci, 365
Murein synthesis
inhibited in *E. coli* by D-alanyl-D-alanine analogs, 887
Mycobacterium marinum
in vitro susceptibility, 529

Nafcillin
S. aureus endocarditis in rabbits, 562
Namalva cells
growth in human albumin medium, 929
interferon production in human albumin medium, 929
Neisseria gonorrhoeae
penicillinase producing, The Netherlands
epidemiology, 789
plasmid characterization, :789
penicillin-binding proteins, 730
pyocin inhibition, 416
rosoxacin, 738
Neomycin
inhibition of adenosine triphosphatase, 532
Neonatal infections
K. pneumoniae, aminoglycoside resistant, 42
Nephrotoxicity

dibekacin compared with gentamicin and amikacin, 983
Netilmicin
diffusion susceptibility test criteria, 487

Oxacillin
killing of exposed *S. aureus* by polymorphonuclear leukocytes, 807

Penicillin
β-lactamase-altered plasmids, resistance, 675
S. aureus susceptibility by Autobac I, 922
S. pneumoniae, binding components, 390
synergy with streptomycin and gentamicin, 944
Penicillin-binding components
S. pneumoniae, 390
Penicillin-binding proteins
in susceptible and resistant *N. gonorrhoeae*, 730
β-lactam antibiotics, interaction in vivo, 629
S. aureus, binding of β-lactams, 834
S. faecalis, binding of β-lactams, 834
S. pneumoniae, 629
Pharmacokinetics, animal
potassium phosphanilate, 746
Pharmacokinetics, human
cefmetazole
impaired renal function, 386
normal subjects, 386
cefotaxime, 369
cefroxadin (CGP 9000) and cephalexin, 656
dibekacin, 372
impaired renal function: cefmetazole, 386
mecillinam, in healthy volunteers, 952
moxalactam, 369
potassium phosphanilate, 746
vidarabine 5′-monophosphate vs. herpes, 709
Phosphonoacetate
herpesviruses, 622
Phosphonoformate
herpesviruses, 622
Phosphonopeptide antibacterial agents
related to alafosfalin, 897
Pichia kluyveri
effect of potassium and sodium ions on toxin, 519
killing action in *S. cerevisiae*, 519
Piperacillin
comparative in vitro appraisal, 493
gram-negative bacilli, 645
inoculum effect on *P. aeruginosa* susceptibility, 893
S. typhi, 493
synergy with β-lactamase inhibitors, 582
pJT2 plasmid
drug resistance, 480
S. typhimurium, 480
Pneumococcal meningitis, experimental
effect on vancomycin in rabbit cerebrospinal fluid, 882
Polyene inhibitors
effect on human erythrocytes, 586
large, 586
small, 586
Polymorphonuclear leukocytes
killing of oxacillin-exposed *S. aureus*, 807
Polyriboinosinic-polyribocytidylic acid complex
toxicity modulated by component alterations, 409
Potassium ions
influence on antifungal amphotericin B, 593
influence on antifungal filipin, 593
P. kluyveri toxin, 519
Potassium phosphanilate
bioavailability, metabolism in humans and animals, 746
Prednisolone
isoniazid metabolism, 661
Probenecid
effect on vancomycin in rabbit cerebrospinal fluid, 882
E-5-Propenyl-2′-deoxyuridine
anti-herpes simplex virus, 957
anti-human cell growth, 957
Proteus rettgeri
β-lactamase, purification and properties, 687
Providencia alcalifaciens
susceptibility compared with other species, 868
Providencia rettgeri
susceptibility compared with other species, 868
Providencia stuartii
susceptibility compared with other species, 868
Pseudomonas aeruginosa
inoculum effect on susceptibility testing, 893
morphology changes under drug synergism, 969
Pyocin
N. gonorrhoeae inhibition, 416

Renal dysfunction
moxalactam pharmacokinetics, 933
Resistance plasmids
erythromycin
C. diphtheriae, 814
diphtheroids, 814
R-factor
K. pneumoniae, multiply resistant outbreak, 926
ε-Rhodomycinone
conversion to daunorubicin glycosides, 454
Ribosomal resistance mutations
related to aminoglycoside uptake, 798
Rifampin
isoniazid metabolism, 661
Ro 13-9904
gram-negative bacilli, pediatrics, 476
in vitro and in vivo studies, 913
in vitro evaluation, 574
Rosaramicin
C. trachomatis activity in vitro, 978
determination in humans, 780
high-pressure liquid chromatography, 780
Rosoxacin
N. gonorrhoeae, *C. trachomatis*, *U. urealyticum*, 738
R1 plasmid
β-lactamase-deficient mutants, 667
penicillin resistance, 675
R plasmids
altered-β-lactamase mutants, penicillin resistance, 675
β-lactamase-deficient mutants in *E. coli*, 667

Saccharomyces cerevisiae

cycloheximide binding to ribosomes, 863
P. kluyveri toxin killing action, 519
ribosomal binding affinity for cycloheximide, 863
Salmonella typhi
piperacillin, 493
Salmonella typhimurium
resistance plasmid pJT2, 480
virulent, in calves, 480
Salt
effect on enterobacterial mecillinam susceptibility, 680
SCE-1365
disposition in rats and dogs, 511
Sch 21420
disk susceptibility test interpretation, 616
Scours
cephamycin C
calves, 397
piglets, 397
Selective protection concept
antivirus chemotherapy, 957
Sensititre dried microtitration trays
MIC accuracy tested, 844
Septicemia
early therapy with carbenicillin-cefazolin-mecillinam, 437
Serratia marcescens
susceptibility to newer cephalosporins, 651
Sodium ions
influence on antifungal amphotericin B, 593
P. kluyveri toxin, 519
Staphylococcus aureus
ampicillin susceptibility by Autobac I, 922
Autobac I susceptibility testing, 922
drug concentration, effect on tolerance, 784
endocarditis
ceforanide, cefazolin, methicillin, nafcillin, 562
gentamicin uptake, 722
growth phase, effect on drug tolerance, 784
killing by polymorphonuclear leukocytes, 807
methicillin resistance, transduction, 424
penicillin-binding protein binding of β-lactams, 834
penicillin susceptibility by Autobac I, 922
small-colony, aminoglycoside-resistant mutants, 722
storage, effect on drug tolerance, 784
Streptococcus faecalis
penicillin-binding protein binding of β-lactams, 834
Streptococcus pneumoniae
micro-broth dilution susceptibility testing, 579
penicillin-binding components, 390
penicillin-binding proteins vs. β-lactams, 629
Streptomyces kitasatoensis
leucomycin production, 691
Streptomycin
synergy with penicillin against enterococci, 944
Synergism
P. aeruginosa morphology changes, 969
Synergy
penicillin/aminoglycosides against enterococci, 944
piperacillin plus β-lactamase inhibitors, 582

Tetracycline
resistance plasmids in group B streptococci, 753
transport in *B. fragilis*, 502
Thymidine
dependent enterococci, 365
Toxicity
modified poly(I)-poly(C) complex, 409

Ureaplasma urealyticum
rosoxacin, 738

Vancomycin
penetration into rabbit cerebrospinal fluid, 882
Varicella-zoster virus
acyclovir, 443
Vidarabine 5′-monophosphate
pharmacology, tolerance, antiviral activity in humans, 709
Viruses, enveloped
inactivation by essential unsaturated fatty acids, 962

Yeast
cycloheximide binding to *S. cerevisiae* ribosomes, 863

ANTIMICROBIAL AGENTS
AND
CHEMOTHERAPY

VOLUME 18

WASHINGTON, DC 20006

1980

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

VOLUME 18 • 1980

EDITORIAL BOARD

LEON H. SCHMIDT, *Editor-in-Chief* (1985)
University of Alabama in Birmingham, Birmingham, Alabama

HERBERT L. ENNIS, *Editor* (1982)
Roche Institute of Molecular Biology, Nutley, New Jersey

JOEL G. FLAKS, *Editor* (1981)
University of Pennsylvania, Philadelphia

ROBERT L. HAMILL, *Editor* (1985)
Eli Lilly & Company, Inc. Indianapolis, Indiana

EDWARD W. HOOK, *Editor* (1981)
University of Virginia, Charlottesville

GEORGE A. JACOBY, JR., *Editor* (1985)
Massachusetts General Hospital Boston, Massachusetts

Vincent T. Andriole (1981)
John P. Anhalt (1981)
Donald Armstrong (1980)
Robert Austrian (1980)
Arthur L. Barry (1980)
John E. Bennett (1981)
Lawrence E. Bryan (1982)
Robert E. Brummitt (1982)
D. Buyske (1980)
Yves Chabbert (1980)
Royston C. Clowes (1980)
C. Glenn Cobbs (1980)
Paul S. Cohen (1980)
Naomi Datta (1981)
Julian Davies (1980)
Lawrence E. Day (1980)
R. Gordon Douglas, Jr. (1980)
Theodore Eickhoff (1982)
Arthur English (1980)
David S. Feingold (1981)
Robert Fekety (1981)
Sydney Finegold (1982)
Robert J. Fitzgerald (1980)
Anthony J. Glazko (1981)
Irving H. Goldberg (1982)
Harry Gooder (1982)
Jack Gwaltney (1980)
Maurice W. Harmon (1981)
Michael Higgins (1980)
Ronald D. Hinsdill (1982)
Richard Hornick (1980)
L. H. Huang (1982)
Milton Huppert (1980)
George Gee Jackson (1980)
Thomas Jones (1980)
William J. Jusko (1980)
Donald Kaye (1982).
Jerome O. Klein (1982)
Vernon Knight (1980)
George S. Kobayashi (1982)
Jordan Konisky (1980)
Matthew E. Levison (1981)
Friedrich C. Luft (1981)
Joan Lusk (1980)
R. Luthy (1980)
Gerald L. Mandell (1980)
Gerald Medoff (1980)
Barbara Minshew (1982)
S. Mitsuhashi (1980)
Robert C. Moellering, Jr. (1982)
R. B. Morin (1982)
Bernard Moss (1981)
John D. Nelson (1980)
Harold C. Neu (1980)
J. F. Niblack (1980)
T. J. Perun (1980)
Charles A. Plate (1982)
Burton M. Pogell (1981)
K. E. Price (1982)
Paul Quie (1980)
W. H. G. Richards (1980)
Mark H. Richmond (1982)
R. W. Rickards (1980)
Richard Roberts (1982)
Ian M. Rollo (1982)
Richard Root (1980)
Jon E. Rosenblatt (1982)
Milton R. J. Salton (1981)
Merle Sande (1982)
Jay Sanford (1980)
Arthur K. Saz (1982)
F. C. Sciavolino (1982)
Oldrich K. Sebek (1980)
William M. Shannon (1980)
Jerome J. Schentag (1982)
John C. Sherris (1980)
Charles Shipman, Jr. (1982)
Robert W. Sidwell (1981)
Walter Siegenthaler (1980)
Sigmund S. Socransky (1980)
P. Frederick Sparling (1981)
R. Sutherland (1982)
Vera L. Sutter (1981)
Morton N. Swartz (1982)
Richard B. Sykes (1982)
Alexander Tomasz (1982)
Ralph Tompsett (1982)
Hamao Umezawa (1981)
Donald Van Harken (1982)
D. Vazquez (1980)
Michael Waring (1981)
John Washington II (1981)
Pamela Waterworth (1982)
Jerry A. Weisbach (1982)
B. Weisblum (1982)
Peter G. Welling (1982)
Richard Wenzel (1980)

Gisella Pollock, *Acting Managing Editor*
Eleanor Tupper, *Production Editor*
1913 I St., NW, Washington, DC 20006

EX OFFICIO

Albert Balows, *President* (1980–1981)
J. Mehsen Joseph, *Secretary*
Frederick C. Neichardt, *President-Elect* (1980–1981)
Brinton M. Miller, *Treasurer*

Antimicrobial Agents and Chemotherapy (ISSN 0066-4804), an interdisciplinary publication of the American Society for Microbiology, 1913 I St., NW, Washington, DC 20006, is devoted to the dissemination of knowledge relating to all aspects of antimicrobial agents, anticancer agents, and chemotherapy. Instructions to Authors are published in the January issue each year. *Antimicrobial Agents and Chemotherapy* is published monthly, and the twelve numbers are divided into two volumes per year. The nonmember subscription price is $65 per year. The member subscription price is $16 per year. Single copies are $6. Correspondence relating to subscriptions, reprints, defective copies, availability of back issues, lost or late proofs, disposition of submitted manuscripts, and general editorial matters should be directed to the ASM Publications Office, 1913 I St., NW, Washington, DC 20006 (area 202 833-9680).

日本：価格は外貨表示とは関係なく円建。

Second class postage paid at Washington, DC 20006, and at additional mailing offices.

Made in the United States of America.

Copyright © 1980, American Society for Microbiology.
All Rights Reserved.

The code at the top of the first page of an article in this journal indicates the copyright owner's consent that copies of the article may be made for personal use, or for personal use of specific clients. This consent is given on the condition, however, that the copier pay the stated per-copy fee through the Copyright Clearance Center, Inc., P.O. Box 765, Schenectady, New York 12301, for copying beyond that permitted by Sections 107 and 108 of the U.S. Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works or for resale.

Biosynthesis; Chemistry; Mechanisms of Action and Resistance

High-Yield Interferon Induction by 10-Carboxymethyl-9-Acridanone in Mice and Hamsters. JERRY L. TAYLOR, CHRISTINE K. SCHOENHERR, AND SIDNEY E. GROSSBERG* 20–26

Effect and Mechanism of Action of Aphidicolin on Yeast Deoxyribonucleic Acid Polymerases. PAOLO PLEVANI,* GIANFRANCO BADARACCO, ENRICO GINELLI, AND SILVIO SORA 50–57

Streptococcus faecium-Derived Antibacterial Substance Antagonistic to Bifidobacteria. RYÔ HARASAWA,* KUNIO SUZUKI, AND TOMOTARI MITSUOKA 58–62

Antibacterial Effect of Scandium and Indium Complexes of Enterochelin on *Klebsiella pneumoniae*. HENRY J. ROGERS,* CHARLOTTE SYNGE, AND VIVIENNE E. WOODS 63–68

Purification and Properties of Cephalosporinase in *Escherichia coli*. SHINZABURO MINAMI, MATSUHISA INOUE, AND SUSUMU MITSUHASHI* 77–80

Penetration of β-Lactam Antibiotics into Their Target Enzymes in *Pseudomonas aeruginosa*: Comparison of a Highly Sensitive Mutant with Its Parent Strain. WILLY ZIMMERMANN 94–100

Cefroxadine (CGP-9000), an Orally Active Cephalosporin. K. YASUDA, S. KURASHIGE, AND S. MITSUHASHI* 105–110

Regulatory Properties of *O*-Acetyl-L-Serine Sulfhydrylase of *Cephalosporium acremonium*: Evidence of an Isoenzyme and Its Importance in Cephalosporin C Biosynthesis. H. DÖBELI AND J. NÜESCH* 111–117

Examination of Parameters Affecting Human Interferon Production with Microcarrier-Grown Fibroblast Cells. DONALD J. GIARD* AND ROBERT J. FLEISCHAKER 130–136

Penicillin-Binding Proteins in Bacteria. NAFSIKA H. GEORGOPAPADAKOU* AND FUNG Y. LIU 148–157

Affinity of Cefoperazone for Penicillin-Binding Proteins. NOBUYUKI MATSUBARA,* SHINZABURO MINAMI, MICHIO MATSUHASHI, MASAYOSHI TAKAOKA, AND SUSUMU MITSUHASHI 195–199

New Translocation Sequence Mediating Tetracycline Resistance Found in *Escherichia coli* Pathogenic for Piglets. SIGRID TUE JØRGENSEN,* BRUNELLO OLIVA, JOHN GRINSTED, AND PETER M. BENNETT 200–205

Physiological Effects and Microbial Susceptibility

In Vitro Antimicrobial Activity of Cefotaxime, a New Cephalosporin. SHINJI MASUYOSHI,* SUSUMU ARAI, MASAKI MIYAMOTO, AND SUSUMU MITSUHASHI 1–8

In Vitro Antimicrobial Susceptibility of *Actinobacillus actinomycetemcomitans*. JØRGEN SLOTS,* RICHARD T. EVANS, PHYLLIS M. LOBBINS, AND ROBERT J. GENCO 9–12

Susceptibility of *Clostridium botulinum* to Thirteen Antimicrobial Agents. JANA M. SWENSON,* CLYDE THORNSBERRY, LORETTA M. MCCROSKEY, CHARLES L. HATHEWAY, AND V. R. DOWELL, JR. 13–19

* Asterisk refers to person to whom inquiries regarding the paper should be addressed.

Inhibition of Clinically Significant Bacterial Organisms In Vitro by 2-Acetylpyridine Thiosemicarbazones. ARTHUR S. DOBEK,* DANIEL L. KLAYMAN, EDWARD T. DICKSON, JR., JOHN P. SCOVILL, AND EDMUND C. TRAMONT 27–36

Cefotaxime: In Vitro Activity and Tentative Interpretive Standards for Disk Susceptibility Testing. PETER C. FUCHS,* ARTHUR L. BARRY, CLYDE THORNSBERRY, RONALD N. JONES, THOMAS L. GAVAN, E. HUGH GERLACH, AND HERBERT M. SOMMERS 88–93

Metronidazole in Treatment Against *Haemophilus vaginalis* (*Corynebacterium vaginale*). EDWARD D. RALPH* AND YURI E. AMATNIEKS 101–104

Bacteriostatic and Bactericidal Activities of 24 Antimicrobial Agents Against *Campylobacter fetus* subsp. *jejuni*. R. VANHOOF,* B. GORDTS, R. DIERICKX, H. COIGNAU, AND J. P. BUTZLER 118–121

Inhibition of Dengue Virus Replication by Amantadine Hydrochloride. WAYNE C. KOFF,* JOE L. ELM, JR., AND SCOTT B. HALSTEAD 125–129

Incidence of Polyene-Resistant Yeasts Recovered from Clinical Specimens. J. D. DICK,* W. G. MERZ, AND R. SARAL 158–163

Beta-Lactamase-Producing Isolates of *Bacteroides* Species from Children. ITZHAK BROOK,* LESLIE CALHOUN, AND PAULA YOCUM 164–166

Radiometric Prescreen for Antitumor Activity with a *Saccharomyces cerevisiae* Mutant Strain. MARILYN K. SPEEDIE,* DOROTHY V. FIQUE, AND RALPH N. BLOMSTER 171–175

Comparative Bactericidal Effects of Azlocillin and Ticarcillin Against *Pseudomonas aeruginosa*. A. R. WHITE, K. R. COMBER, AND R. SUTHERLAND* 182–189

In Vitro Susceptibility Testing of *Paracoccidioides brasiliensis* to Sulfonamides. ANGELA RESTREPO M.* AND MARÍA D. ARANGO 190–194

Microdilution Aminoglycoside Susceptibility Testing of *Pseudomonas aeruginosa* and *Escherichia coli* with a Cation-Supplemented Inoculum. JOHN E. CHERNE AND LANCE R. PETERSON* 210–211

Pharmacology and Therapeutics

Antibacterial Activity of Miloxacin. AKIO IZAWA, YOKO KISAKI, KENJI IRIE, YASUKO EDA, TAKENARI NAKAGOME, AND TOSHIAKI KOMATSU* 37–40

Absorption and Excretion of Miloxacin in Mice, Rats, and Dogs. AKIO IZAWA, AKIRA YOSHITAKE, AND TOSHIAKI KOMATSU* 41–44

Determination of Miloxacin and Metabolites in Human Serum and Urine by High-Pressure Liquid Chromatography. AKIRA YOSHITAKE,* KAZUO KAWAHARA, FUMIAKI SHONO, ISAO UMEDA, AKIO IZAWA, AND TOSHIAKI KOMATSU 45–49

Biliary Elimination of Mezlocillin: an Experimental and Clinical Study. J. M. BROGARD, J. KOPFERSCHMITT, J. P. ARNAUD, M. DORNER, AND J. LAVILLAUREIX* 69–76

Effects of Impaired Renal Function, Hemodialysis, and Peritoneal Dialysis on the Pharmacokinetics of Mezlocillin. DIETER KAMPF,* RANDOLF SCHURIG, KLAUS WEIHERMÜLLER, AND DIETER FÖRSTER 81–87

Synergistic Action of Nafcillin and Ampicillin Against Ampicillin-Resistant *Haemophilus influenzae* Type b Bacteremia and Meningitis in Infant Rats. RAM YOGEV* AND WILLIAM J. KABAT 122–124

Direct-Current Bactericidal Effect on Intact Skin. L. BOLTON,* B. FOLENO, B. MEANS, AND S. PETRUCELLI 137–141

Ineffectiveness of Adenine Arabinoside and Adenine Arabinoside 5′-Monophosphate in Simian Varicella Infection. KENNETH F. SOIKE,* AMBHAN D. FELSENFELD, SUSAN GIBSON, AND PETER J. GERONE 142–147

Clinical Trial of Piperacillin with Acquisition of Resistance by *Pseudomonas* and Clinical Relapse. GARY L. SIMON, DAVID R. SNYDMAN, FRANCIS P. TALLY, AND SHERWOOD L. GORBACH* 167–170

Comparative Low-Dose Nephrotoxicities of Gentamicin, Tobramycin, and Amikacin. G. H. HOTTENDORF* AND LEON L. GORDON 176–181

In Vitro Effect of Rifampin on Serum Bilirubin Determinations. STEVEN MEISEL,* ROBERT PUPKOFF, AND JOHN SVAAN 206–207

Protection of Staphylococci Ingested by Macrophages from Bactericidal Action of Rifampin. EDWARD L. PESANTI 208–209

Hypoxanthine-Arabinoside Pharmacokinetics After Adenine Arabinoside Administration to a Patient with Renal Failure. GEORGE R. ARONOFF,* JAMES J. SZWED, ROBERT L. NELSON, EDWIN L. MARCUS, AND STUART A. KLEIT 212–214

Volume 18 Contents for August **Number 2**

Biosynthesis; Chemistry; Mechanisms of Action and Resistance

Plasmid-Determined Resistance to Fosfomycin in *Serratia marcescens*. CARMEN MENDOZA, JUAN M. GARCIA, JUAN LLANEZA, FRANCISCO J. MENDEZ, CARLOS HARDISSON, AND JOSÉ M. ORTIZ* 215–219

Mode of Action of Copper Complexes of Some 2,2′-Bipyridyl Analogs on *Paracoccus denitrificans*. HENDRIK SMIT, HENDERIKUS VAN DER GOOT,* WIJBE T. NAUTA, PIETER J. PIJPER, SIJBE BALT, MARTINUS W. G. DE BOLSTER, ADRIAN H. STOUTHAMER, HENK VERHEUL, AND RONALD D. VIS 249–256

Antiviral Activity of Antilipidemic Compounds on Herpes Simplex Virus Type 1. J. KURT MEHL, DONALD T. WITIAK, VINCENT V. HAMPARIAN, AND JOHN H. HUGHES* 269–275

How Partially Inhibitory Concentrations of Chloramphenicol Affect the Growth of *Escherichia coli*. ROBERT J. HARVEY* AND ARTHUR L. KOCH 323–337

Physiological Effects and Microbial Susceptibility

Characterization of Three Different β-Lactamases from the *Bacteroides fragilis* Group. BARBRO OLSSON-LILJEQUIST, KATHRINE DORNBUSCH, AND CARL ERIK NORD* 220–225

Classification of Polyene Antibiotics According to Their Synergistic Effect in Combination with Bleomycin A2 or Fusidic Acid. SHINICHI AKIYAMA,* TOSHIKO TABUKI, MASAE KANEKO, SOHTARO KOMIYAMA, AND MICHIHIKO KUWANO 226–230

Antifungal and Antibacterial Activities of Diarylamidine Derivatives. JOSEF ANNÉ,* ERIK DE CLERCQ, HENDRIK EYSSEN, AND OTTO DANN 231–239

Antimycoplasmal Activity of Dimethylphenols in a Tracheal Explant Culture System. C. COE AGEE,* J. A. ENGELHARDT, AND M. G. GABRIDGE 243–248

Substrate-Labeled Fluorescent Immunoassay for Amikacin in Human Serum. STEPHAN G. THOMPSON* AND JOHN F. BURD ... 264–268

Antiviral Activity of Arildone on Deoxyribonucleic Acid and Ribonucleic Acid Viruses. K. S. KIM,* V. J. SAPIENZA, AND R. I. CARP 276–280

Effects of Steroid Hormones on *Neisseria gonorrhoeae*. PAUL G. LYSKO AND STEPHEN A. MORSE* 281–288

In Vitro Antibacterial Activity and Susceptibility of the Cephalosporin Ro 13-9904 to Beta-Lactamases. KEVIN SHANNON, ANNA KING, CHRISTINE WARREN, AND IAN PHILLIPS* 292–298

In Vitro Activity of Chloramphenicol and Thiamphenicol Analogs. HAROLD C. NEU* AND KWUNG P. FU 311–316

Activity of 2-Acetylpyridine Thiosemicarbazones Against *Trypanosoma rhodesiense* In Vitro. ROBERT A. CASERO, JR., DANIEL L. KLAYMAN,* GEORGE E. CHILDS, JOHN P. SCOVILL, AND ROBERT E. DESJARDINS 317–322

Comparison of In Vitro Activity of Sch 21420, a Gentamicin B Derivative, with Those of Amikacin, Gentamicin, Netilmicin, Sisomicin, and Tobramycin. C. THORNSBERRY,* A. L. BARRY, R. N. JONES, C. N. BAKER, R. E. BADAL, AND R. R. PACKER .. 338–345

Effect of Clavulanic Acid on Minimal Inhibitory Concentrations of 16 Antimicrobial Agents Tested Against *Legionella pneumophila*. DONALD J. POHLOD,* LOUIS D. SARAVOLATZ, EDWARD L. QUINN, AND MARGARET M. SOMERVILLE 353–354

In Vitro Activity of Ro 13-9904, Cefuroxime, Cefoxitin, and Ampicillin Against *Neisseria gonorrhoeae*. THOMAS T. YOSHIKAWA,* SHARON A. SHIBATA, PAMELA HERBERT, AND PHYLLIS A. OILL 355–356

Effects of Antituberculosis and Antileprosy Drugs on Mycobacteriophage D29 Growth. HUGO L. DAVID,* SABINE CLAVEL, FRANÇOISE CLEMENT, AND JOSÉ MONIZ-PEREIRA 357–359

Pharmacology and Therapeutics

Pharmacokinetics of Ro 13-9904, a Broad-Spectrum Cephalosporin. M. SEDDON, R. WISE,* A. P. GILLETT, AND R. LIVINGSTON ... 240–242

Comparative Activities of Cefotiam and Cefazolin Against Urinary Tract Infections with *Proteus mirabilis* in Mice. TOMOYUKI IWAHI AND KANJI TSUCHIYA* 257–263

Chemotherapy of *Babesia microti* Infections in Mongolian Jirds. TRENTON K. RUEBUSH II,* PETER G. CONTACOS, AND EDGAR A. STECK 289–291

Potential of Mezlocillin as Empiric Single-Agent Therapy in Febrile Granulocytopenic Cancer Patients. JAMES C. WADE,* STEPHEN C. SCHIMPFF, KATHRYN A. NEWMAN, CLARENCE L. FORTNER, MARCIA R. MOODY, VIOLA MAE YOUNG, AND PETER H. WIERNIK 299–306

Ampicillin Therapy of Experimental Enterococcal Endocarditis. ROBERT R. TIGHT 307–310

Comparative Nephrotoxicities of High-Dose Netilmicin and Tobramycin in Rats. RICHARD A. PARKER,* DAVID N. GILBERT, DONALD C. HOUGHTON, GEORGE A. PORTER, AND WILLIAM M. BENNETT 346–348

Phlebitis Induced by Parenteral Treatment with Flucloxacillin and Cloxacillin: a Double-Blind Study. ÅKE SVEDHEM,* KJELL ALESTIG, AND MARIANNE JERTBORN 349–352

Resistance to Penicillin and Identification of Penicillinase-Producing *Neisseria gonorrhoeae* Among Clinical Isolates in Thailand. JOHN W. CRUM,* CHIRAPHUN DUANGMANI, SOMNUK VIBULYASEKHA, AND KALAYA SUTHISOMBOON 360–361

Errata

Purification and Properties of a New β-Lactamase from *Pseudomonas cepacia*. K. HIRAI, S. IYOBE, M. INOUE, AND S. MITSUHASHI 362

Bacteriostatic and Bactericidal Activities of β-Lactam Antibiotics Enhanced by the Addition of Low Concentrations of Gentamicin. GOHTA MASUDA, KISHIO NAKAMURA, TARO YAJIMA, AND KAZUE SAKU 363

Effect of Orally Administered Probenecid on the Pharmacokinetics of Cefoxitin. PETER H. VLASSES, ANNE M. HOLBROOK, JOHN J. SCHROGIE, J. DOUGLAS ROGERS, ROGER K. FERGUSON, AND WILLIAM B. ABRAMS 363

Volume 18 Contents for September **Number 3**

Biosynthesis; Chemistry; Mechanisms of Action and Resistance

Penicillin-Binding Components of Penicillin-Susceptible and -Resistant Strains of *Streptococcus pneumoniae*. P. B. PERCHESON AND L. E. BRYAN* 390–396

Pyocin Inhibition of *Neisseria gonorrhoeae*: Mechanism of Action. STEPHEN A. MORSE,* BENJAMIN V. JONES, AND PAUL G. LYSKO 416–423

Transduction of Methicillin Resistance in *Staphylococcus aureus*: Recipient Effectiveness and Beta-Lactamase Production. GEORGE C. STEWART AND EUGENE D. ROSENBLUM* 424–432

5′-Amino-5′-Deoxythymidine: Synthesis, Specific Phosphorylation by Herpesvirus Thymidine Kinase, and Stability to pH of the Enzymically Formed Diphosphate Derivative. MING S. CHEN, GEORGE T. SHIAU, AND WILLIAM H. PRUSOFF* 433–436

Biosynthesis of Daunorubicin Glycosides: Role of ε-Rhodomycinone. JEFFREY C. MCGUIRE,* MONICA C. THOMAS, RONALD M. STROSHANE, BRUCE K. HAMILTON, AND RICHARD J. WHITE 454–464

Cell-Free Cyclizatin of δ-(L-α-Aminodipyl)-L-Cysteinyl-D-Valine to Isopenicillin N. YOSUKE SAWADA, JACK E. BALDWIN, PUSHPA D. SINGH, NADINE A. SOLOMON, AND ARNOLD L. DEMAIN* 465–470

pJT2: Unusual H1 Plasmid in a Highly Virulent Lactose-Positive and Chloramphenicol-Resistant *Salmonella typhimurium* Strain from Calves. J. F. TIMONEY,* DIANE E. TAYLOR, S. SHIN, AND P. MCDONOUGH 480–482

Physiological Effects and Microbial Susceptibility

Incidence of Thymidine-Dependent Enterococci Detected on Mueller-Hinton Agar with Low Thymidine Content. RITA C. HALTINER, PAULA C. MIGNEAULT, AND RICHARD G. ROBERTSON* 365–368

Induction of β-Lactamase by Various β-Lactam Antibiotics in *Enterobacter cloacae*. SHINZABURO MINAMI,* AKIRA YOTSUJI, MATSUHISA INOUE, AND SUSUMU MITSUHASHI 382–385

Susceptibility of *Legionella pneumophila* to Twenty Antimicrobial Agents. PAUL H. EDELSTEIN* AND RICHARD D. MEYER 403–408

In Vitro Susceptibility of Varicella-Zoster Virus to Acyclovir. KAREN K. BIRON* AND GERTRUDE B. ELION 443–447

Lack of Toxicity of Acyclovir to Granulocyte Progenitor Cells in Vitro. ROBERT W. MCGUFFIN, FAITH M. SHIOTA, AND JOEL D. MEYERS* 471–473

Prevalence of Ampicillin-Resistant Strains of *Haemophilus influenzae* Causing Systemic Infection. STEPHEN J. LERMAN,* JAN M. BRUNKEN, AND MITZI BOLLINGER 474–475

In Vitro Susceptibility of Gram-Negative Bacilli from Pediatric Patients to Moxalactam, Cefotaxime, Ro 13-9904, and Other Cephalosporins. SHARON SHELTON, JOHN D. NELSON,* AND GEORGE H. MCCRACKEN, JR. 476–479

In Vitro Activity of Cefoperazone Against Nonfermenters and *Aeromonas hydrophila*. ROBERT J. FASS 483–486

Tentative Interpretive Criteria for the Diffusion Susceptibility Test Using 30-μg Netilmicin Disks. RONALD N. JONES,* ARTHUR L. BARRY, AND CLYDE THORNSBERRY 487–490

Pharmacology and Therapeutics

Comparison of Cefotaxime and Moxalactam Pharmacokinetics and Tissue Levels. R. WISE,* S. BAKER, AND R. LIVINGSTON 369–371

Pharmacokinetic Studies with Dibekacin, a New Aminoglycoside, After Intravenous and Intramuscular Administration to Human Volunteers. MITSUYOSHI GOTO,* MASATOSHI SUGIYAMA, AND TAKASHI ISHIZAKI 372–376

New In Vitro Kinetic Model for Evaluating Bactericidal Efficacy of Antibiotics. TAKEO MURAKAWA, HIROSHI SAKAMOTO, TOSHIHARU HIROSE, AND MINORU NISHIDA* 377–381

Pharmacokinetics of Cefmetazole in Normal Subjects and in Patients with Impaired Renal Function. MITSUO OHKAWA,* MATSUO ORITO, TOSHIAKI SUGATA, MASAYOSHI SHIMAMURA, MASARU SAWAKI, EINOSUKE NAKASHITA, KYOICHI KURODA, AND KUNIHIRO SASAHARA 386–389

Cephamycin C Treatment of Induced Enterotoxigenic Colibacillosis (Scours) in Calves and Piglets. THOMAS M. JACKS,* KLAUS-DIETER SCHLEIM, FREDERICK R. JUDITH, AND BRINTON M. MILLER 397–402

Modified Polyriboinosinic-Polyribocytidylic Acid Complex: Modulation of Toxicity for Rabbits by Alterations in Components. BIENVENIDO G. GATMAITAN, HILTON B. LEVY, AND A. MARTIN LERNER* 409–415

Carbenicillin plus Cefazolin with or Without Mecillinam as an Early Treatment of Bacteremia Caused by Gram-Negative Organisms: Randomized Double-Blind Study. J. KLASTERSKY,* L. COPPENS, F. MEUNIER-CARPENTIER, AND A. P. MENDAY 437–442

Prophylaxis Against Enterococcal Endocarditis: Comparison of the Aminoglycoside Component of Parenteral Antimicrobial Regimens. JORGE MURILLO, HAROLD C. STANDIFORD,* H. PRESTON HOLLEY, BEVERLY A. TATEM, AND ELLIS S. CAPLAN 448–453

Errata

Inhibition of Clinically Significant Bacterial Organisms In Vitro by 2-Acetylpyridine Thiosemicarbazones. ARTHUR S. DOBEK, DANIEL L. KLAYMAN, EDWARD T. DICKSON, JR., JOHN P. SCOVILL, AND EDMUND C. TRAMONT 491

Absorption and Disposition Kinetics of Amoxicillin in Normal Human Subjects. A. ARANCIBIA, J. GUTTMAN, G. GONZÁLEZ, AND C. GONZÁLEZ 491

Combined Antibacterial Activity of Amoxicillin with Clavulanic Acid Against Ampicillin-Resistant Strains. M. MATSUURA, H. NAKAZAWA, T. HASHIMOTO, AND S. MITSUHASHI 491

Volume 18 Contents for October 1980 Number 4

Biosynthesis; Chemistry; Mechanism of Action and Resistance

Tetracycline Transport in *Bacteroides fragilis*. FRANÇOISE FAYOLLE, GAETANO PRIVITERA,* AND MADELEINE SEBALD 502–505

Enzymatic Method for Rapid and Sensitive Determination of β-Lactam Antibiotics. JEAN-MARIE FRÈRE, DANIEL KLEIN, AND JEAN-MARIE GHUYSEN* 506–510

Effects of Potassium and Sodium Ions on the Killing Action of a *Pichia kluyveri* Toxin in Cells of *Saccharomyces cerevisiae*. EVERT J. MIDDELBEEK,* ANS Q. H. CRÜTZEN, AND GODFRIED D. VOGELS 519–524

Influence of Chemical Modification of N^{α}-Cocoyl-L-Arginine Ethyl Ester on Its Hepatitis B Surface Antigen-Inactivating Effect. YOSHIKAZU SUGIMOTO* AND SHIGESHI TOYOSHIMA 525–528

Neomycin Inhibition of Adenosine Triphosphatase: Evidence for a Neomycin-Phospholipid Interaction. JAMES J. LIPSKY* AND PAUL S. LIETMAN 532–535

Klebsiella Neonatal Infections: Mechanism of Broadening Aminoglycoside Resistance. D. J. HARDY, R. J. LEGEAI, AND R. J. O'CALLAGHAN* 542–548

Relationship Between Metronidazole Metabolism and Bactericidal Activity. EWAN J. T. CHRYSTAL, RONALD L. KOCH, MARTHA A. MCLAFFERTY, AND PETER GOLDMAN* 566–573

Characterization of Chloramphenicol-Resistant *Haemophilus influenzae*. MARILYN C. ROBERTS,* CHRISTINA D. SWENSON, LYNN M. OWENS, AND ARNOLD L. SMITH 610–615

In Vivo Interaction of β-Lactam Antibiotics with the Penicillin-Binding Proteins of *Streptococcus pneumoniae*. RUSSELL WILLIAMSON, REGINE HAKENBECK, AND ALEXANDER TOMASZ* 629–637

Physiological Effects and Microbial Susceptibility

Comparative In Vitro Appraisal of Piperacillin, Including Its Activity Against *Salmonella typhi*. ROY G. ROBINSON, JEAN SAUNDERS, ROBERT CASSEL, COLIN S. BLOCK, AND HENDRIK J. KOORNHOF* 493–501

In Vitro Susceptibility of *Mycobacterium marinum* to Eight Antimicrobial Agents. WILLIAM J. SANDERS AND EMANUEL WOLINSKY* 529–531

Enhancement of Activity Against Influenza Viruses by Combinations of Antiviral Agents. FREDERICK G. HAYDEN, R. GORDON DOUGLAS, JR.,* AND RUTH SIMONS 536–541

In Vitro Activity of *N*-Formimidoyl Thienamycin (MK0787), a Crystalline Derivative of Thienamycin. VICTOR W. HORADAM, JERRY D. SMILACK,* CAROL L. MONTGOMERY, AND JURGEN WERRINGLOER 557–561

In Vitro Evaluation of Ro 13-9904. ANNE M. HINKLE AND GERALD P. BODEY* 574–578

Antimicrobial Susceptibility Testing of *Streptococcus pneumoniae* by Micro-Broth Dilution. MARTHA M. TARPAY,* DAVID F. WELCH, AND MELVIN I. MARKS 579–581

Synergistic Activity of Piperacillin in Combination with β-Lactamase Inhibitors. HAROLD C. NEU* AND KWUNG P. FU 582–585

Permeabilizing and Hemolytic Action of Large and Small Polyene Antibiotics on Human Erythrocytes. JANINA BRAJTBURG,* GERALD MEDOFF, GEORGE S. KOBAYASHI, SVETLANA ELBERG, AND CAROLYNN FINEGOLD 586–592

Influence of Extracellular K^+ or Mg^{2+} on the Stages of the Antifungal Effects of Amphotericin B and Filipin. JANINA BRAJTBURG,* GERALD MEDOFF, GEORGE S. KOBAYASHI, AND SVETLANA ELBERG 593–597

Interpretive Standards for Disk Susceptibility Tests with Sch 21420 and Amikacin. ARTHUR L. BARRY,* CLYDE THORNSBERRY, RONALD N. JONES, AND E. HUGH GERLACH 616–621

Comparative Studies of Interferon and Three Antiviral Agents on Neurotropic and Oncogenic Herpesviruses. MUTHIAH D. DANIEL,* LAWRENCE A. FALK, NORVAL W. KING, RUTH TAMULEVICH, JAMES S. HOLLAND, AND J. GEORGE BEKESI 622–628

Bactericidal Activity of Cerumen. TUU-JYI CHAI* AND TOBY C. CHAI 638–641

In Vitro Activity of *N*-Formimidoyl Thienamycin (MK0787). FRANCIS P. TALLY,* NILDA V. JACOBUS, AND SHERWOOD L. GORBACH 642–644

Comparative In Vitro Activity of Moxalactam, Cefotaxime, Cefoperazone, Piperacillin, and Aminoglycosides Against Gram-Negative Bacilli. TERRANCE O. KURTZ, DREW J. WINSTON, JANET A. HINDLER, LOWELL S. YOUNG, WILLIAM L. HEWITT, AND WILLIAM J. MARTIN* 645–648

Pharmacology and Therapeutics

Metabolic Fate of SCE-1365, a New Broad-Spectrum Cephalosporin, After Parenteral Administration to Rats and Dogs. SHIGEHARU TANAYAMA,* KIYOSHI YOSHIDA, KIMIKO ADACHI, AND TAKAO KONDO 511–518

Therapeutic Effects of Cefotiam and Cefazolin on Experimental Pneumonia Caused by *Klebsiella pneumoniae* DT-S in Mice. TAKESHI NISHI AND KANJI TSUCHIYA* 549–556

Comparison of Ceforanide, Cefazolin, Methicillin, and Nafcillin in *Staphylococcus aureus* Endocarditis Therapy in Rabbits. J. CARRIZOSA, W. D. KOBASA, AND D. KAYE* 562–565

Erythro-9-(2-Hydroxy-3-Nonyl)Adenine Alone and in Combination with 9-β-D-Arabinofuranosyladenine in Treatment of Systemic Herpesvirus Infections in Mice. WILLIAM M. SHANNON,* GUSSIE ARNETT, FRANK M. SCHABEL, JR., THOMAS W. NORTH, AND SEYMOUR S. COHEN 598–603

Animal Model Distinguishing In Vitro from In Vivo Carbenicillin-Aminoglycoside Interactions. JOHN A. PIEPER, RONALD A. VIDAL, AND JEROME J. SCHENTAG* 604–609

Erratum

In Vitro Antimicrobial Susceptibility of *Actinobacillus actinomycetemcomitans*. JØRGEN SLOTS, RICHARD T. EVANS, PHYLLIS M. LOBBINS, AND ROBERT J. GENCO 649

Volume 18 Contents for November Number 5

Biosynthesis; Chemistry; Mechanisms of Action and Resistance

Characterization of β-Lactamase-Deficient (*bla*) Mutants of the R Plasmid R1 in *Escherichia coli* K-12 and Comparison with Similar Mutants of RP1. IAN CROWLESMITH AND T. G. B. HOWE* 667–674

Quantitative Correlation Between Penicillin Resistance and β-Lactamase Activity Specified by the R Plasmids R1, R1 *bla-45*, and RP1 in *Escherichia coli* K-12. IAN CROWLESMITH AND T. G. B. HOWE* 675–679

Purification and Biochemical Properties of β-Lactamase Produced by *Proteus rettgeri*. MASAYUKI MATSUURA, HISASHI NAKAZAWA, MATSUHISA INOUE,* AND SUSUMU MITSUHASHI 687–690

Gentamicin Uptake in Wild-Type and Aminoglycoside-Resistant Small-Colony Mutants of *Staphylococcus aureus*. MICHAEL H. MILLER,* STEPHEN C. EDBERG, LAURA J. MANDEL, CAREN F. BEHAR, AND NEAL H. STEIGBIGEL 722–729

Penicillin-Binding Proteins of Penicillin-Susceptible and Intrinsically Resistant *Neisseria gonorrhoeae*. THOMAS J. DOUGHERTY,* ANTJE E. KOLLER, AND ALEXANDER TOMASZ 730–737

Inhibition of Cellular α and Virally Induced Deoxyribonucleic Acid Polymerases by the Triphosphate of Acyclovir. MARTY H. ST. CLAIR,* PHILLIP A. FURMAN, CAROL M. LUBBERS, AND GERTRUDE B. ELION 741–745

Identification of Tetracycline-Resistant R-Plasmids in *Streptococcus agalactiae* (Group B). VICKERS BURDETT 753–760

Synthesis of 3-*O*-Demethylfortimicins. JERRY R. MARTIN,* PAULETTE JOHNSON, JACK TADANIER, AND ALMA GOLDSTEIN 761–765

Penicillinase-Producing *Neisseria gonorrhoeae* in the Netherlands: Epidemiology and Genetic and Molecular Characterization of Their Plasmids. J. D. A. VAN EMBDEN,* B. VAN KLINGEREN, M. DESSENS-KROON, AND L. J. VAN WIJNGAARDEN 789–797

Interaction Between Aminoglycoside Uptake and Ribosomal Resistance Mutations. M. H. AHMAD, ANGELIKA RECHENMACHER, AND AUGUST BÖCK* 798–806

Plasmids in *Corynebacterium diphtheriae* and Diphtheroids Mediating Erythromycin Resistance. JOHN SCHILLER, NEAL GROMAN,* AND MARIE COYLE 814–821

Growth and Antifungal Homoazasterol Production in *Geotrichum flavo-brunneum*. R. J. RODRIGUEZ AND L. W. PARKS* 822–828

Binding of β-Lactam Antibiotics to Penicillin-Binding Proteins of *Staphylococcus aureus* and *Streptococcus faecalis*: Relation to Antibacterial Activity. NAFSIKA H. GEORGOPAPADAKOU* AND FUNG Y. LIU 834–836

Physiological Effects and Microbial Susceptibility

Comparative Susceptibilities of Clinical Isolates of *Serratia marcescens* to Newer Cephalosporins, Alone and in Combination with Various Aminoglycosides. SHELDON M. MARKOWITZ* AND DENISE J. SIBILLA 651–655

Effect of Beta-Lactamase and Salt on Mecillinam Susceptibility of Enterobacterial Strains. GER P. A. BONGAERTS* AND KRISTIANE M. BRUGGEMAN-OGLE 680–686

Stimulation of Leucomycin Production by Magnesium Phosphate and Its Relevance to Nitrogen Catabolite Regulation. SATOSHI ŌMURA,* YOSHITAKE TANAKA, CHIAKI KITAO, HARUO TANAKA, AND YUZURU IWAI 691–695

Relative Resistance to Erythromycin in *Chlamydia trachomatis*. ALY MOURAD, RICHARD L. SWEET, NANCY SUGG, AND JULIUS SCHACHTER* 696–698

Method for Reliable Determination of Minimal Lethal Antibiotic Concentrations. RICHARD D. PEARSON, ROY T. STEIGBIGEL,* HENRY T. DAVIS, AND STANLEY W. CHAPMAN 699–708

Tentative Interpretive Standards for Disk Susceptibility Tests with Moxalactam (LY127935). A. L. BARRY,* C. THORNSBERRY, R. N. JONES, AND E. H. GERLACH 716–721

In Vitro Antimicrobial Activity of Rosoxacin Against *Neisseria gonorrhoeae*, *Chlamydia trachomatis*, and *Ureaplasma urealyticum*. RICHARD A. DOBSON,* JOHN R. O'CONNOR, SHARON A. POULIN, RUTH B. KUNDSIN, THOMAS F. SMITH, AND PAUL E. CAME 738–740

Comparative Antimicrobial Activity of *O*-Demethylfortimicin A, a Derivative of Fortimicin A. ROLAND L. GIROLAMI* AND JOHN M. STAMM 766–772

Compound A49759, a 3-*O*-Demethyl Derivative of Fortimicin A: In Vitro Comparison with Six Other Aminoglycoside Antibiotics. RONALD N. JONES,* CLYDE THORNSBERRY, ARTHUR L. BARRY, RICHARD R. PACKER, CAROLYN N. BAKER, AND ROBERT E. BADAL 773–779

High-Pressure Liquid Chromatographic Method for Determination of Rosaramicin in Humans. C. LIN,* H. KIM, D. SCHUESSLER, E. ODEN, AND S. SYMCHOWICZ 780–783

Effect of Storage and Changes in Bacterial Growth Phase and Antibiotic Concentrations on Antimicrobial Tolerance in *Staphylococcus aureus*. C. GLEN MAYHALL* AND ELAINE APOLLO 784–788

Killing of Oxacillin-Exposed Staphylococci in Human Polymorphonuclear Leukocytes. VICTOR LORIAN* AND BARBARA ATKINSON 807–813

Susceptibility of *Eikenella corrodens* to Newer Beta-Lactam Antibiotics. ELLIE J. C. GOLDSTEIN,* MYLES E. GOMBERT, AND EMMANUEL O. AGYARE 832–833

Effect of *N*-Formimidoyl Thienamycin (MK0787) on β-Lactamases and Activity Against β-Lactamase-Producing Strains. M. TODA,* K. SATO, H. NAKAZAWA, M. INOUE, AND S. MITSUHASHI 837–838

Pharmacology and Therapeutics

Pharmacokinetic Comparison of Cefroxadin (CGP 9000) and Cephalexin by Simultaneous Administration to Humans. JEAN B. LECAILLON,* JEAN L. HIRTZ, JEAN P. SCHOELLER, GUY HUMBERT, AND WOLFGANG VISCHER 656–660

Effect of Prednisolone and Rifampin on Isoniazid Metabolism in Slow and Rapid Inactivators of Isoniazid. G. RAGHUPATI SARMA, S. KAILASAM, N. G. K. NAIR, A. S. L. NARAYANA, AND S. P. TRIPATHY* 661–666

Pharmacology, Tolerance, and Antiviral Activity of Vidarabine Monophosphate in Humans. RICHARD J. WHITLEY,* BRUCE C. TUCKER, ARLYN W. KINKEL, NANCY H. BARTON, ROBERT F.

PASS, JOHN D. WHELCHEL, C. GLENN COBBS, ARNOLD G. DIETHELM, AND ROBERT A. BUCHANAN 709–715

Bioavailability and Metabolism of Potassium Phosphanilate in Laboratory Animals and Humans. FRANCIS H. LEE,* DONALD R. VAN HARKEN, MICHAEL VASILJEV, ROBERT D. SMYTH, AND G. H. HOTTENDORF 746–752

Influence of Food on Absorption of Erythromycin Ethyl Succinate. PHILIP J. THOMPSON, KEITH R. BURGESS, AND GRAHAM E. MARLIN* 829–831

Erratum

Factors Affecting Gentamicin Assay. LENNART NILSSON 839

Volume 18 **Contents for December** **Number 6**

Biosynthesis; Chemistry; Mechanisms of Action and Resistance

Purification and Properties of a Cephalosporinase from *Enterobacter cloacae*. SHINZABURO MINAMI,* MATSUHISA INOUE, AND SUSUMU MITSUHASHI 853–857

Uptake of Indolmycin in Gram-Positive Bacteria. ROLF G. WERNER 858–862

Binding of Cycloheximide to Ribosomes from Wild-Type and Mutant Strains of *Saccharomyces cerevisiae*. WALTER STÖCKLEIN* AND WOLFGANG PIEPERSBERG 863–867

Inhibition of Peptidoglycan Synthesis in Ether-Permeabilized *Escherichia coli* Cells by Structural Analogs of D-Alanyl-D-Alanine. HELMUT PELZER* AND WOLFGANG REUTER 889–892

R-Factor Responsible for an Outbreak of Multiply Antibiotic-Resistant *Klebsiella pneumoniae*. MARY-ANNE COURTNEY, JAMES R. MILLER, JAMES SUMMERSGILL, JULIO MELO, MARTIN J. RAFF, AND ULDIS N. STREIPS* 926–929

Replacement of Animal Serum Proteins by Human Albumin for Growth and Interferon Production by Namalva Cells. A. KIRK FIELD,* EDGAR M. SCATTERGOOD, CHARLES J. HOPKE, ALFRED A. TYTELL, AND MAURICE R. HILLEMAN 930–932

Anti-Herpes Simplex Virus and Anti-Human Cell Growth Activity of *E*-5-Propenyl-2′-Deoxyuridine and the Concept of Selective Protection in Antivirus Chemotherapy. YUNG-CHI CHENG,* SUSAN GRILL, JERRY RUTH, AND DONALD E. BERGSTROM 957–961

Interaction of Polyunsaturated Fatty Acids with Animal Cells and Enveloped Viruses. A. KOHN,* J. GITELMAN, AND M. INBAR 962–968

Physiological Effects and Microbial Susceptibility

In Vitro Susceptibility *Haemophilus equigenitalis*, the Causative Organism of Contagious Equine Metritis 1977, to Antimicrobial Agents.—HENRY J. DABERNAT,* CATHERINE F. DELMAS, DANIEL J. TAINTURIER, AND MARIE B. LARENG 841–843

Comparison of Sensititre Dried Microtitration Trays with a Standard Agar Method for Determination of Minimum Inhibitory Concentrations of Antimicrobial Agents. DAVID S. REEVES, ALAN HOLT, MARTIN J. BYWATER, RICHARD WISE, MARGARET N. LOGAN, JENNY M. ANDREWS, AND JOHN M. BROUGHALL* 844–852

Differences Among *Providencia* Species in Their In Vitro Susceptibilities to Five Antibiotics. J. L. PENNER* AND M. A. PRESTON 868–871

In Vitro Antagonism by Erythromycin of the Bactericidal Action of Antimicrobial Agents Against Common Respiratory Pathogens. JOHN R. COHN,* DONALD L. JUNGKIND, AND JOHN S. BAKER 872–876

Klebsiella Species: Antimicrobial Susceptibilities, Bactericidal Kinetics, and In Vitro Inactivation of Beta-Lactam Agents. ANAND P. PANWALKER, GARY M. TRAGER,* AND PRISCILLA E. POREMBSKI 877–881

Influence of Inoculum Size on Activity of Cefoperazone, Cefotaxime, Moxalactam, Piperacillin, and *N*-Formimidoyl Thienamycin (MK0787) Against *Pseudomonas aeruginosa*. MICHAEL L. CORRADO,* SHELDON H. LANDESMAN, AND CHARLES E. CHERUBIN 893–896

Phosphonopeptide Antibacterial Agents Related to Alafosfalin: Design, Synthesis, and Structure-Activity Relationships. FRANK R. ATHERTON, MICHAEL J. HALL, CEDRIC H. HASSALL,* SIMON W. HOLMES, ROBERT W. LAMBERT, WILLIAM J. LLOYD, AND PETER S. RINGROSE 897–905

Activity of Mecillinam Alone and in Combination with Other β-Lactam Antibiotics. ROBERT J. FASS 906–912

Two-Hospital Study of *Staphylococcus aureus* Susceptibility to Penicillin and Ampicillin by Autobac I. PATRICIA C. HARRIS* AND LYNN B. SEALEY 922–925

CI-867, a New Semisynthetic Penicillin: In Vitro Studies. SUSANNE S. WEAVER AND GERALD P. BODEY* 939–943

Synergy of Penicillin and Decreasing Concentrations of Aminoglycosides Against Enterococci from Patients with Infective Endocarditis. JOSEPH Y. MATSUMOTO,* WALTER R. WILSON, ALAN J. WRIGHT, JOSEPH E. GERACI, AND JOHN A. WASHINGTON II 944–947

Antimicrobial Susceptibility of *Campylobacter jejuni* and *Campylobacter fetus* subsp. *fetus* to Eight Cephalosporins with Special Reference to Species Differentiation. M. A. KARMALI, S. DE GRANDIS, AND P. C. FLEMING* 948–951

Morphological Expressions of Antibiotic Synergism Against *Pseudomonas aeruginosa* as Observed by Scanning Electron Microscopy. STEVEN J. WAISBREN, DAVID J. HURLEY, AND BURTON A. WAISBREN* 969–975

Corynebacterium equi: In Vitro Susceptibility to Twenty-Six Antimicrobial Agents. JOHN B. WOOLCOCK* AND MALCOLM D. MUTIMER 976–977

In Vitro Activity of Rosaramicin Against *Chlamydia trachomatis*. W. R. BOWIE 978–979

Pharmacology and Therapeutics

Effect of Meningitis and Probenecid on the Penetration of Vancomycin into Cerebrospinal Fluid in Rabbits. DANIEL P. KRONTZ AND LARRY J. STRAUSBAUGH* 882–886

Ro 13-9904, a Long-Acting Broad-Spectrum Cephalosporin: In Vitro and In Vivo Studies. PETER ANGEHRN,* PETER J. PROBST, ROLAND REINER, AND RUDOLF L. THEN 913–921

Pharmacokinetics of Moxalactam in Subjects with Various Degrees of Renal Dysfunction. W. KLINE BOLTON,* W. MICHAEL SHELD, DANIEL A. SPYKER, TERRY L. OVERBY, AND MERLE A. SANDE 933–938

Pharmacokinetics of Mecillinam in Healthy Subjects. JOHN G. GAMBERTOGLIO,* STEVEN L. BARRIERE, EMIL T. LIN, AND JOHN E. CONTE, JR. 952–956

Cefoperazone Concentrations in Bile and Gall Bladder Wall After Intravenous Administration. TAKASHI NAKAMURA,* IKUO HASHIMOTO, YASUO SAWADA, JIROH MIKAMI, EIICHI BEKKI, SADAKO HIRASAWA, HIROMU ABE, AND YASUO WATANABE ... 980–982

Comparative Nephrotoxicities of Dibekacin, Amikacin, and Gentamicin in a Rat Model. LAURA L. RANKIN,* FRIEDRICH C. LUFT, MOO N. YUM, AND LINDA L. ISAACS 983–985

Erratum

pJT2: Unusual H1 Plasmid in a Highly Virulent Lactose-Positive and Chloramphenicol-Resistant *Salmonella typhimurium* Strain from Calves. J. F. TIMONEY, DIANE E. TAYLOR, S. SHIN, AND P. MCDONOUGH 986

INDEX TO DATE OF ISSUE

Month	Date of Issue	Pages
July	30 July 1980	1–214
August	4 September 1980	215–363
September	22 September 1980	365–491
October	13 October 1980	493–649
November	13 November 1980	651–839
December	26 December 1980	841–987